Exosomal cardiac troponins as biomarkers of heart disease

Assessing cardiac troponin in exosomes offers improved heart disease diagnosis by accurately identifying myocardial strain and ischemia, addressing the limitations of existing blood-based measurements.

WO2026238961A1PCT designated stage Publication Date: 2026-11-19UNIVERSITY OF HEIDELBERG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/064205
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-15
Publication Date
2026-11-19

Smart Images

  • Figure 00000053_0000
    Figure 00000053_0000
  • Figure 00000054_0000
    Figure 00000054_0000
  • Figure 00000055_0000
    Figure 00000055_0000
Patent Text Reader

Abstract

The present invention relates to a method for assessing a heart disease in a subject, the method comprising (a) determining an amount of a cardiac troponin (cTn) in exosomes (exosomal cTn) in a sample of a bodily fluid of said subject; and (b) thereby assessing said heart disease. The present invention also relates to a computer-implemented method, a database, a system, and a kit related to said method.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Universitat Heidelberg 1 UH17314PC

[0002] Exosomal cardiac Troponins as Biomarkers of Heart Disease

[0003] The present invention relates to a method for assessing a heart disease in a subject, the method comprising (a) determining an amount of a cardiac troponin (cTn) in exosomes (exosomal cTn) in a sample of a bodily fluid of said subject; and (b) thereby assessing said heart disease. The present invention also relates to a computer-implemented method, a database, a system, and a kit related to said method.

[0004] The measurement of cardiac troponin (cTn) concentration in systemic venous blood has become a key component in the evaluation of patients with acute and chronic cardiovascular disease. Modern high-sensitivity cTn assays specifically quantify cardiac isoforms of the troponin subunits. Experimental evidence supports the thesis that release of cTn is exclusively due to irreversible cell death; some observations, however, have propelled the hypothesis that a release may also occur without overt myocardial necrosis, for instance as a result of reversible myocardial ischemia or pressure overload (Wu et al., Intensive Care Med 2001; Jaffe et al.,. Clin Chem 2012).

[0005] Recently, extracellular vesicles (EV) have been isolated from peripheral blood that originated from vital cells and carry a distinct cargo within a lipid bilayer, dependent on their specific cell of origin. The membrane-enclosed or intramembranous content of EV encompasses various molecules entrapped within exosomes in circulation prone to extracellular degradation over time. Western blot and immunoassays using commercial antibodies have also shown that these EV contain cardiac troponin T (Lennon et al. 2022, doi:10.1002 / ctm2.979; Zara et al. 2021 doi:10.3390 / ijms22158065, Anselmo et al., Eur Heart J 2021; 42(28):2780-2792. doi: 10.1093 / eurheartj / ehab247).

[0006] Nonetheless, there is a need in the art for new biomarkers in heart disease patients to support patient management and to facilitate in particular cross-diagnosis. It is therefore an objective of the present invention to provide improved means and methods for assessing heart disease avoiding at least in part the drawbacks of the prior art. This problem is solved by the means and methods of the present invention, with the features of the independent claims. PreferredUniversitat Heidelberg 2 UH17314PC

[0007] embodiments, which might be realized in an isolated fashion or in any arbitrary combination are listed in the dependent claims.

[0008] In accordance, the present invention relates to a method for assessing a heart disease in a subject, the method comprising

[0009] (a) determining an amount of a cardiac troponin (cTn) in exosomes (exosomal cTn) in a sample of a bodily fluid of said subject; and

[0010] (b) thereby assessing said heart disease.

[0011] In general, terms used herein are to be given their ordinary and customary meaning to a person of ordinary skill in the art and, unless indicated otherwise, are not to be limited to a special or customized meaning. As used in the following, the terms “have”, “comprise” or “include” or any arbitrary grammatical variations thereof are used in a non-exclusive way. Thus, these terms may both refer to a situation in which, besides the feature introduced by these terms, no further features are present in the entity described in this context and to a situation in which one or more further features are present. As an example, the expressions “A has B”, “A comprises B” and “A includes B” may both refer to a situation in which, besides B, no other element is present in A (i.e. a situation in which A solely and exclusively consists of B) and to a situation in which, besides B, one or more further elements are present in entity A, such as element C, elements C and D or even further elements. Also, as is understood by the skilled person, the expressions "comprising a" and "comprising an" preferably refer to "comprising one or more", i.e. are equivalent to "comprising at least one". In accordance, expressions relating to one item of a plurality, unless otherwise indicated, preferably relate to at least one such item, more preferably a plurality thereof; thus, e.g. identifying "a cell" relates to identifying at least one cell, preferably to identifying a multitude of cells; also, the term "determining a biomarker X" relates to determining at least biomarker X and may optionally comprise determining further biomarkers, symptoms, and other data as deemed appropriate by the skilled person.

[0012] Further, as used in the following, the terms "preferably", "more preferably", "most preferably", "particularly", "more particularly", "specifically", "more specifically" or similar terms are used in conjunction with optional features, without restricting further possibilities. Thus, features introduced by these terms are optional features and are not intended to restrict the scope of the claims in any way. The invention may, as the skilled person will recognize, be performed by using alternative features. Similarly, features introduced by "preferably" or similar expressionsUniversitat Heidelberg 3 UH17314PC

[0013] are intended to be optional features, without any restriction regarding further embodiments of the invention, without any restrictions regarding the scope of the invention and without any restriction regarding the possibility of combining the features introduced in such way with other optional or non-optional features of the invention.

[0014] As used herein, if not otherwise indicated, the term "about" relates to the indicated value with the commonly accepted technical precision in the relevant field, preferably relates to the indicated value ± 20%, more preferably ± 10%, most preferably ± 5%. Further, the term "essentially" indicates that deviations having influence on the indicated result or use are absent, i.e. potential deviations do not cause the indicated result to deviate by more than ± 20%, more preferably ± 10%, most preferably ± 5%. Thus, “consisting essentially of’ means including the components specified but excluding other components except for materials present as impurities, unavoidable materials present as a result of processes used to provide the components, and components added for a purpose other than achieving the technical effect of the invention. For example, a composition defined using the phrase “consisting essentially of’ encompasses any known acceptable additive, excipient, diluent, carrier, and the like. Preferably, a composition consisting essentially of a set of components will comprise less than 5% by weight, more preferably less than 3% by weight, even more preferably less than 1% by weight, most preferably less than 0.1% by weight of non-specified component s).

[0015] The degree of identity (e.g. expressed as "%identity") between two biological sequences, preferably DNA, RNA, or amino acid sequences, can be determined by algorithms well known in the art. Preferably, the degree of identity is determined by comparing two optimally aligned sequences over a comparison window, where the fragment of sequence in the comparison window may comprise additions or deletions (e.g., gaps or overhangs) as compared to the sequence it is compared to for optimal alignment. The percentage is calculated by determining, preferably over the whole length of the polynucleotide or polypeptide as specified herein, the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman (1981), by the homology alignment algorithm of Needleman and Wunsch (1970), by the search for similarity method of Pearson and Lipman (1988), by computerized implementations of these algorithms (e.g. BLAST, GAP,Universitat Heidelberg 4 UH17314PC

[0016] BESTFIT, PASTA, or TFASTA), or by visual inspection. Given that two sequences have been identified for comparison, GAP and BESTFIT are preferably employed to determine their optimal alignment and, thus, the degree of identity. Preferably, the default values of 5.00 for gap weight and 0.30 for gap weight length are used. More preferably, the Basic Local Alignment Search Tool (BLAST) implementation is used with default parameter values for alignment. In the context of biological sequences referred to herein, the term "essentially identical" indicates a %identity value of at least 90%, preferably at least 95%, more preferably at least 98%, most preferably at least 99%. As will be understood, the term essentially identical includes 100% identity. The aforesaid applies to the term "essentially complementary" mutatis mutandis.

[0017] The methods specified herein, preferably, are in vitro methods, more preferably ex vivo methods. Some methods or steps thereof, may, however also be performed in vivo. The method steps may, in principle, be performed in any arbitrary sequence deemed suitable by the skilled person, but preferably are performed in the indicated sequence; also, one or more, preferably all, of said steps may be assisted or performed by automated equipment. Moreover, the methods may comprise steps in addition to those explicitly mentioned above. Also, the methods may be comprised in other methods; e.g. the method for assessing heart disease may be comprised in a method of monitoring a subject at risk of suffering from heart disease. Also, the methods are preferably at least partially, more preferably fully, computer-implemented, wherein the term “computer-implemented”, as used herein, preferably means that the method is carried out at least partially in an automated fashion on a data processing unit which is, typically, comprised in a computer or similar data processing device, such as an evaluation device as described herein below. The data processing device shall obtain results of determining at least one biomarker, e.g. a value for the amount of the at least one biomarker. Such values can be the amounts, relative amounts or any other calculated value reflecting the amount as described elsewhere herein in detail. Accordingly, it is to be understood that the methods described herein do not necessarily require the determination of amounts for the biomarkers but rather may use values of amounts determined earlier, which may e.g. be obtained from a storage means and / or from a database. As the skilled person understands, however, it is preferred that such values determined earlier were preferably determined at most 1 day, preferably at most 12 hours, more preferably at most 6 hours, before a method described herein is performed, i.e. the values determined earlier preferably are the values of the most recent determination performed for the subject.Universitat Heidelberg 5 UH17314PC

[0018] The term “assessing”, as used herein, refers to establishing information about the status of the indicated disease or condition, in particular its severity, symptoms, localization, prognosis and / or other relevant information. Said assessing preferably is an aid in diagnosing the indicated disease; as the skilled person will understand, establishing a diagnosis may be based on the aforesaid assessment, however, preferably is based on the aforesaid assessment in combination with further diagnostic information, such as anamnesis data, general physical and / or mental examination findings, and / or additional metabolic data. Thus, assessing heart disease may relate to assessing whether a subject suffers from heart disease, is at risk of suffering from heart disease, exhibits a medical condition which deteriorates with respect to heart disease, to establishing the disease stage of heart disease of a subject, and / or establishing a prognosis with respect to heart disease. Accordingly, assessing as used herein includes diagnosing heart disease, predicting the risk for developing heart disease, and / or predicting any deterioration of the health condition of the subject, in particular, with respect to signs and symptoms accompanying heart disease. Thus, the method as specified may in particular be comprised in a method of monitoring heart disease. Assessment referred to herein may also be the assessment of a risk of developing heart disease. More preferably, assessment may be the prediction of the risk that the subject’s health condition will deteriorate. Moreover, it will be understood that if the risk of developing heart disease or risk of the deterioration of the health condition is predicted, typically, the prediction is made within a predictive window. More typically, said predictive window is of from 1 hour to 4 weeks, preferably of from 3 hours to 7 days.

[0019] As referred to herein, assessing heart disease preferably may also refer to establishing information about differentiating heart disease from a non-heart disease disorder as specified herein below, i.e. said assessing preferably is an aid in differentially diagnosing the indicated disease; as the skilled person will understand, establishing a differential diagnosis may be based on the aforesaid assessment, however, preferably is based on the aforesaid assessment in combination with further diagnostic information, preferably as specified herein above. Thus, assessing heart disease may relate to assessing whether a subject suffers from heart disease or from a non-heart disease disorder. Accordingly, assessing as used herein includes classifying heart disease from at least one non-heart disease disorder as specified herein below. Preferably, in particular in case of differentiating heart disease from non-heart disease disorders, the subject was diagnosed to show at least one symptom indicative of heart disease and / or of a non-heart disease disorder. Thus, the method of assessing heart disease may in particular be applied to aUniversitat Heidelberg 6 UH17314PC

[0020] sample of a subject from a pre-selected subgroup of subjects requiring or profiting from differential diagnosis. Non-heart diseases potentially requiring differential diagnosis from the heart diseases as specified herein are, in principle, textbook knowledge and include, e.g., acute or chronic renal failure, pneumothorax, pulmonary embolism, aortic dissection, and the like.

[0021] As referred to herein, assessing heart disease preferably may also refer to establishing information about differentiating between subtypes of heart disease as specified herein below, i.e. said assessing preferably is an aid in differentially diagnosing the indicated disease subtypes; as the skilled person will understand, establishing a differential diagnosis may be based on the aforesaid assessment, however, preferably is based on the aforesaid assessment in combination with further diagnostic information, preferably as specified herein above. Thus, assessing heart disease may relate to assessing whether a subject suffers from a first subtype of heart disease or a second subtype of heart disease. Accordingly, assessing as used herein includes classifying subtypes of heart disease. Preferably, in particular in case of differentiating of subtypes of heart disease, the subject was diagnosed to show at least one symptom shared by said subtypes.

[0022] Assessing as referred to herein may relate to a rule-in assessment, i.e. to identifying a subject as belonging to a group of subjects sharing a common feature, e.g. suffering from heart disease. Assessing, however, may also relate to a rule-out assessment, i.e. to identifying a subject as not belonging to a group of subjects sharing a common feature, e.g. as not suffering from heart disease. Thus, the assessment may aid in establishing a diagnosis; the assessment may, however, also aid in excluding a diagnosis. The above applies mutatis mutandis to differential diagnosis, i.e. the differential diagnosis may comprise or be a rule-in assessment, i.e. to identifying a subject as suffering from heart disease or as suffering from a non-heart disease disorder; it may, however, may also comprise or be a rule-out assessment, i.e. to identifying a subject as not suffering from heart disease or as not suffering from a non-heart disease disorder. Thus, the assessment may aid in establishing a differential diagnosis. As the skilled person is aware of, e.g. excluding heart disease in a subject showing symptoms thereof as such already may be of help to decide on the further course of treatment.

[0023] In view of the above, assessing heart disease in particular may comprise or be aiding in diagnosis of heart disease, preferably to be applied in a specialist or tertiary care setting, in particular with access to a laboratory environment where automated assays can be run; and / orUniversitat Heidelberg 7 UH17314PC

[0024] an aid in the diagnosis and assessment of the severity of heart disease in subjects with signs and symptoms of heart disease, preferably in conjunction with other laboratory findings and clinical assessments. Preferably, assessing comprises excluding heart disease, preferably comprises identifying a subject not suffering from heart disease; comprises diagnosing heart disease, and / or comprises staging heart disease. More preferably, assessing comprises differentiating between heart disease and non-heart disease disorders as specified elsewhere herein. Even more preferably assessing is classifying heart disease. Nonetheless, preferably, the non-heart disease disorders do not comprise elevated serum cTnT levels secondary to acute or chronic renal failure; thus, preferably, assessing does not comprise differentiating between heart disease and advanced or end-stage renal disease.

[0025] As will be understood by those skilled in the art, the assessment made in accordance with the present invention, although usually preferred to be, may not be correct for 100% of the investigated subjects. However, the term preferably requires that a statistically significant portion of subjects can be correctly assessed. Whether a portion is statistically significant can be determined without further ado by the person skilled in the art using various well-known statistic evaluation tools, e.g., determination of confidence intervals, p-value determination, Student's t-test, Mann-Whitney test, etc. Details may be found in Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York 1983. Typically envisaged confidence intervals are at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%. The p-values are, typically, 0.1, 0.05, or 0.01.

[0026] As discussed in more detail elsewhere herein, the disease assessed preferably is heart disease. Thus, assessing heart disease preferably is providing data aiding in diagnosing heart disease, is excluding heart disease, is excluding at least one type of heart disease, is providing information aiding a decision on further diagnostic and / or treatment steps, or is diagnosing heart disease. As the skilled person understands, diagnosing heart disease may relate to establishing the fact that a subject is suffering from heart disease; more preferably, diagnosing heart disease comprises diagnosing or aiding in diagnosing which subtype of heart disease a subject suffers from, even more preferably comprises diagnosing or aiding in diagnosing which heart disease a subject suffers from. Thus, assessing heart disease preferably is differentiating between a heart disease associated with myocardial strain and a heart disease associated with myocardial ischemia, wherein said heart disease associated with myocardial strain preferably is an atrial fibrillation and / or wherein said heart disease associated with myocardial ischemia preferably isUniversitat Heidelberg 8 UH17314PC

[0027] a myocardial infarction. Thus, assessing may in particular comprise providing a differential diagnosis between atrial fibrillation and myocardial infraction. Thus, preferably, assessing heart disease is assessing arrhythmia and / or is assessing myocardial infarction.

[0028] The term "heart disease" is understood by the skilled person. Preferably, the heart disease requires medical intervention, i.e. preferably is a heart disease requiring medical treatment within 12 hours, preferably within 6 hours, more preferably within 3 hours, to prevent permanent harm to a subject, wherein said permanent harm preferably includes possible death. More preferably, the heart disease is an acute heart disease, i.e. is a disease ongoing at the time the sample is taken from the subject. Most preferably, the heart disease is an acute heart disease known or suspected to require medical intervention. Preferably, the heart disease is a heart disease associated with myocardial strain, preferably an atrial fibrillation; also preferably, the heart disease is a heart disease associated with myocardial ischemia, more preferably a myocardial infarction. Thus, the heart disease may in particular be a disease of a subject presenting to a medical practitioner with unspecific symptoms pointing to an involvement of the heart; more preferably symptoms which do not allow exclusion of a heart disease associated with myocardial strain and / or do not allow exclusion of a heart disease associated with myocardial ischemia. In view of the description herein, the skilled person understands that e.g. heart disease associated with myocardial strain, in particular atrial fibrillation, and heart disease associated with myocardial ischemia, in particular myocardial infarction, are subtypes of heart disease.

[0029] The term “subject”, as used herein, relates to a vertebrate animal, preferably to a mammal. More preferably, the subject is a primate and, most preferably, a human. The subject may be an apparently healthy subject, however, preferably, is a subject known or suspected to be at risk of suffering from heart disease. Risk factors for developing heart disease are known in the art, e.g. from standard medical text books and include e.g. nicotine use, elevated blood pressure, hyperlipoproteinemia, elevated lipoprotein (a), diabetes mellitus, polygenic familial predisposition, chronic kidney disease associated with chronic hyperphosphatemia, chronic inflammatory diseases and / or residual systemic inflammation. Thus, preferably, the subject is at risk of suffering from heart disease, i.e., preferably, the subject is a subject from a population with a prevalence of heart disease of at least 0.5%, preferably at least 1%, more preferably at least 5%, even more preferably at least 10%, most preferably at least 20%. Corresponding populations are known in the art and include in particular populations having a geneticUniversitat Heidelberg 9 UH17314PC

[0030] predisposition, in particular populations with a history of myocardial infarction and / or ischemic stroke of a first-degree relative before the age of 65, more preferably before the age of 55. Also preferably, the subject at risk of suffering from heart disease is a subject at least 40 years old, more preferably, at least 50 years old. More preferably, the subject at risk of suffering from heart disease is a subject suffering from angina pectoris, acute-onset and / or exercise-induced chest pain, acute onset and / or exercise-induced dyspnea, heart palpitations, symptoms associated with acute-onset vertigo, sickness, vomitus, prostration, or syncope. Also preferably, the subject is a subject in need of differential diagnosis of heart disease. Thus, the subject preferably is a subject showing at least one symptom of heart disease and a non-heart disease disorder, and / or showing at least one shared symptom of subtypes of heart disease, preferably as specified herein above. Preferably, the subject is known or suspected to be suffering from heart disease and / or is known or suspected to suffer from a non-heart disease disorder. The skilled person selects the appropriate assessment for a particular subject dependent on the subject's symptoms and existing diagnoses, including tentative diagnoses. Thus, the subject preferably shows or showed symptoms of a heart disease, preferably at the time said sample was obtained. In accordance, the subject may in particular be a subject presenting to a medical practitioner with unspecific symptoms pointing to an involvement of the heart; more preferably symptoms which do not allow exclusion of a heart disease associated with myocardial strain and / or do not allow exclusion of a heart disease associated with myocardial ischemia.

[0031] The term “determining”, as used herein, refers to semiquantitative or quantitative determination of a biomarker referred to herein. Determining a biomarker may be carried out by any technique which allows for establishing a measure of quantity of a biomarker in a semiquantitative or quantitative manner; thus, determining may in particular be determining an amount as specified herein below. Suitable techniques depend on the molecular nature and the properties of the biomarker and are discussed elsewhere herein in more detail. Biomarkers to be determined in accordance with the present invention, i.e. at least one cardiac Troponin, are as such known in the art. Moreover, methods for the determination of the biomarker are known to the skilled person as well. For example, the biomarker can be measured as described in the Examples section.

[0032] Preferably, the biomarker may be determined by detecting the amount of molecular species of the biomarker, or of fragments thereof. In the context of the present description, a biomarker or a detectable fragment thereof used for determining a biomarker may also be referred to as anUniversitat Heidelberg 10 UH17314PC

[0033] "analyte". E.g., small molecule biomarkers or fragments of biological macromolecules, e.g. peptides, may be detected as such or as their ions in mass spectrometry (MS). For polypeptide biomarkers, detection of fragments thereof may be technically easier to put into practice. However, also other methods for detecting the amount of molecular species of the biomarker are available, including chromatographic separation techniques such as liquid chromatography (LC), high performance liquid chromatography (HPLC), gas chromatography (GC), thin layer chromatography, and / or size exclusion or affinity chromatography, coupled to appropriate detection devices. Such a detection device may e.g. be a photometer, e.g. a UV / VIS-photometer or an MS device. Appropriate devices and methods are known in the art. Further suitable methods comprise measuring a physical or chemical property specific for the biomarker, such as its precise molecular mass or an NMR spectrum. Suitable devices for determining a biomarker comprise, preferably, biosensors, optical devices coupled to immunoassays, biochips, analytical devices such as mass-spectrometers, NMR-analyzers, surface plasmon resonance measurement equipment, and chromatography devices. The amount of a biomarker may, however, also be determined in an activity assay, in particular in case the biomarker has catalytic, e.g. enzymatic, or signaling activity.

[0034] Preferably, determining the amount of a polypeptide biomarker such as a cardiac Troponin comprises contacting said biomarker with a detection agent. The term “detection agent”, as used herein, refers to any compound which allows determination, preferably specific determination, of an amount of a biomarker. Thus, the detection compound may in particular be a reaction substrate, e.g. in case the biomarker has catalytic activity, e.g. is an enzyme. More preferably, the detection agent is an agent binding, preferably specifically, to a biomarker or analyte thereof. Preferably, the detection agent is not chemically modified by the biomarker, i.e. the detection agent preferably is not a substrate of a chemical activity of the biomarker.

[0035] A detection agent according to the present invention can be any compound, e.g., a polypeptide, nucleic acid, or small molecule, binding to the biomarker described herein. Preferred detection agents include antibodies, nucleic acids, peptides or polypeptides such as receptors or binding partners for the peptide or polypeptide and fragments thereof comprising the binding domains for the peptides, and aptamers, e.g. nucleic acid or peptide aptamers. Methods to prepare such detection agents are well-known in the art. For example, identification and production of suitable antibodies or aptamers for an antigen of interest is also offered by commercial suppliers, and suitable detection agents for the biomarkers referred to herein are commerciallyUniversitat Heidelberg 11 UH17314PC

[0036] available, such as those used herein in the Examples. If necessary, the person skilled in the art is familiar with methods to develop derivatives of detection agents with higher affinity or specificity. For example, random mutations can be introduced into the nucleic acids, peptides, or polypeptides comprised in detection agents. These derivatives can then be tested for binding according to screening procedures known in the art, e.g. phage display.

[0037] As referred to herein, the term "antibody" includes both polyclonal and monoclonal antibodies, as well as fragments thereof, such as Fv, Fab and F(ab)2 fragments that are capable of binding the analyte of interest, in particular the cTn. Also included are single chain antibodies as well as genetically re-engineered chimeric human / mouse antibodies, wherein amino acid sequences of a non-human donor antibody exhibiting a desired antigen-specificity are combined with sequences of a human acceptor antibody. The donor sequences will usually include at least the antigen-binding amino acid residues of the donor, but may comprise other structurally and / or functionally relevant amino acid residues of the donor antibody as well, such as the complementarity determining regions (CDRs), or the variable regions of an antibody. Such hybrids can be prepared by methods well known in the art.

[0038] Preferably, the detection agent binds specifically to the biomarker, preferably to cardiac Troponin T and / or cardiac Troponin I, preferably to human cardiac Troponin T and / or human cardiac Troponin I. Specific binding, as referred to herein, means that the detection agent essentially does not bind to (“cross-react” with) another polypeptide, i.e. any non-cTn compound present in the sample to be analyzed. In particular, the detection agent, in particular the antibody, shall specifically bind to human cardiac Troponin T and / or human cardiac Troponin I, but shall not bind to the isoforms of Troponin T and I, respectively, from skeletal muscle. Preferably, the specifically bound peptide or polypeptide should be bound with at least 3 times higher, more preferably at least 10 times higher, even more preferably at least 50 times higher, affinity than any other relevant peptide or polypeptide; thus, preferably, the signal generated in a specific assay determining a cTn preferably is at least 3 times higher, more preferably at least 10 times higher and even more preferably at least 50 times higher than any signal generated with any other compound present in a sample, and / or generated with a sample known to not comprise a cTn. As the skilled person understands, the aforesaid difference in signal may depend on the concentration of the biomarker such as a cTn in a sample relative to any interferents. Thus, specific determination is preferably performed with an assay above the assay's detection limit, wherein said detection limit preferably is selected such that at theUniversitat Heidelberg 12 UH17314PC

[0039] detection limit, the signal generated by a sample comprising the biomarker provides for a signal at least 3 times the signal of a sample not comprising said biomarker. Nonetheless, non-specific binding may be tolerable if the biomarker can still be distinguished and measured unequivocally, e.g. according to its size on a Western Blot, or by its relatively much higher, preferably at least 5-fold higher, signal compared to interferents in the sample.

[0040] Binding of a detection agent may be measured directly, e.g. by NMR or surface plasmon resonance. Measurement of the binding of a ligand may be performed by an analyzing device of a system disclosed herein. Thereafter, an amount of the measured binding may be calculated by an evaluation device of a system disclosed herein.

[0041] The detection agent may be adapted for binding to a solid substrate, in which said detection agent may also be referred to as "capture agent". Materials for manufacturing solid supports are well known in the art and include, inter alia, commercially available column materials, polystyrene beads, latex beads, magnetic beads, colloid metal particles, glass and / or silicon chips and surfaces, nitrocellulose strips, membranes, sheets, duracytes, wells and walls of reaction trays, plastic tubes etc. Suitable methods for immobilizing said capture agent are well known and include, but are not limited to ionic, hydrophobic, covalent interactions and the like. It is also contemplated to use “suspension arrays” as arrays according to the present invention (Nolan 2002, Trends Biotechnol. 20(l):9-12). In such suspension arrays, the carrier, e.g. a microbead or microsphere, is present in suspension. The array consists of different microbeads or microspheres, optionally labelled, carrying different detection agents. Methods of producing such arrays, for example based on solid-phase chemistry and photo-labile protective groups, are generally known, e.g. from US 5,744,305.

[0042] The detection agent may also be coupled covalently or non-covalently to a label allowing detection and measurement of the detection agent. Such a detection agent comprising a label may also be referred to as "indicator agent" herein. Labeling may be done by direct or indirect methods, which are known to the skilled person. The indicator agent may also be "tagged" with one or more tags as known in the art. Such tags may then be targets for higher order detection agents. Suitable tags include biotin, digoxygenin, His-Tag, Glutathion-S-Transferase, FLAG, GFP, myc-tag, influenza A virus haemagglutinin (HA), maltose binding protein, and the like. In the case of a polypeptide, the tag is preferably at the N-terminus and / or C-terminus. Suitable labels are any labels detectable by an appropriate detection method. Typical labels include goldUniversitat Heidelberg 13 UH17314PC

[0043] particles, latex beads, acridan ester, luminol, ruthenium, enzymatically active labels, radioactive labels, magnetic labels ("e.g. magnetic beads", including paramagnetic and superparamagnetic labels), and fluorescent labels. Enzymatically active labels include e.g. horseradish peroxidase, alkaline phosphatase, beta-Galactosidase, Luciferase, and derivatives thereof. Suitable substrates for detection include diamino-benzidine (DAB), 3,3'-5,5'-tetramethylbenzidine, NBT-BCIP (4-nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl-phosphate, e.g. available as ready-made stock solution from Roche Diagnostics, CDP-Star™ (Amersham Biosciences), ECF™ (Amersham Biosciences). A suitable enzymesubstrate combination may result in a colored reaction product, fluorescence or chemoluminescence, which can be measured according to methods known in the art (e.g. using a light-sensitive film or a suitable camera system). As for measuring the enzymatic reaction, the criteria given above apply analogously. Typical fluorescent labels include fluorescent proteins, such as GFP and its derivatives, and fluorescent dyes, such as e.g. Cy3, Cy5, Texas Red, Fluorescein, and the Alexa dyes (e.g. Alexa 568). Further fluorescent labels are available e.g. from Molecular Probes (Oregon). Also, the use of quantum dots as fluorescent labels is contemplated. Typical radioactive labels include35S,125I,32P,33P and the like. A radioactive label can be detected by any method known and appropriate, e.g. a light-sensitive film or a phosphor imager. Suitable measurement methods include precipitation (particularly immunoprecipitation), electrochemiluminescence (ECL, also referred to as electro-generated chemiluminescence), RIA (radioimmunoassay), ELISA (enzyme-linked immunosorbent assay), sandwich enzyme immune tests, electro-chemiluminescence sandwich immunoassays (ECLIA), dissociation-enhanced lanthanide fluoro immuno assay (DELFIA), scintillation proximity assay (SPA), turbidimetry, nephelometry, latex-enhanced turbidimetry or nephelometry, and solid phase immune tests. Further methods known in the art (such as gel electrophoresis, 2D gel electrophoresis, SDS polyacrylamid gel electrophoresis (SDS-PAGE), Western Blotting, and mass spectrometry), can be used alone or in combination with labelling or other detection methods as described above.

[0044] The term "amount" is used herein in a broad sense including each and every measure of quantity deemed appropriate by the skilled person. Thus, the amount may be an absolute amount, e.g. in a sample or in a defined volume of sample, a relative amount, e.g. as compared to a reference amount and / or to a calibration amount, a concentration, preferably an absolute concentration, which may e.g. be expressed in pg / mL cTn of sample, a relative concentration, or any value or parameter which correlates thereto or can be derived therefrom, preferably by standardUniversitat Heidelberg 14 UH17314PC

[0045] mathematical operations. Such values or parameters comprise intensity signal values from specific physical or chemical properties obtained from the biomarker during determining as specified herein, e.g. by direct measurements, e.g., intensity values in mass spectra or NMR spectra. Moreover, encompassed are all values or parameters which are obtained by indirect measurements specified elsewhere herein, e.g., response levels determined from biological readout systems in response to the biomarker, or intensity signals obtained from specifically bound ligands, such as detection agents. It is to be understood that values correlating to the aforementioned amounts or parameters can also be obtained by all standard mathematical operations.

[0046] As the skilled person is aware of, it may, however, not be necessary to express an amount in terms of quantity of material; the amount may also be expressed as a signal intensity in an assay, e.g. as ECL units, as counts of radioactivity, or even as arbitrary units. As the skilled person will understand, measures not directly indicating amounts or concentrations may in particular be used in case all relevant values of amounts are expressed by the same measure. Preferably, the method comprises a step of calibrating the amounts measured to provide at least one quantity of material expression; thus, an assay may be configured to provide the amount of cTn determined as ECL units; preferably, in such case, the assay is additionally calibrated to allow to correlate said ECL units with cTn concentrations, e.g. expressed as ng / mL. Preferably, determining an amount is performed as described herein, preferably by the system described herein, whereby an analytic device determines the amount based on contacting and measuring steps described.

[0047] It is well known in the art that amounts of a cardiac Troponin as determined with a specific assay may show some variance. Therefore, reference amounts and the amounts determined in a sample preferably are approximate amounts. Accordingly, reference amounts and the amounts determined in a sample as set forth herein, preferably, may differ by 30% (+ / -30%). More preferably, the amounts may differ by 20% (+ / -20%). Even more preferably, the amounts may differ by 10% (+ / -10%). Most preferably, the amounts may differ by 5% (+ / -5%). It is also envisaged that the amounts may differ by 2 or 1%. Preferably, the amounts are the exact amounts.

[0048] The term “cardiac Troponin” is understood by the skilled person. Preferably, the term refers to all Troponin isoforms expressed in cells of the heart, preferably in the cardiomyocytes. TheseUniversitat Heidelberg 15 UH17314PC

[0049] isoforms are well characterized in the art, e.g. in Anderson 1995, Circulation Research, vol. 76, no. 4: 681-686 and Ferrieres 1998, Clinical Chemistry, 44: 487-493. Preferably, cardiac Troponin refers to cardiac Troponin T (cTnT) and / or cardiac Troponin I (cTnl), more preferably to cardiac Troponin T. It is to be understood that isoforms of Troponins may be determined together, i.e. simultaneously, or sequentially, or individually, i.e. without determining the other isoform. Amino acid sequences for human Troponin T and human Troponin I are disclosed in Anderson 1995, loc. cit. and Ferrieres 1998, loc. cit.; the amino acid sequence of cardiac muscle isoform 1 of cTnT, one of several known isoforms, is available under Genbank Acc No. NP 001393652.1; the amino acid sequence of a cardiac muscle isoform of cTnl is available under Genbank Acc No. AAAI 6157.1.

[0050] The term cardiac Troponin further encompasses variants of the aforementioned specific Troponins, i.e., preferably, of Troponin I, and more preferably, of Troponin T. Such variants have at least the same essential biological and / or immunological properties as the specific cardiac Troponins. In particular, they share the same essential immunological properties if they are detectable by the same specific immunological assays referred to in this specification, e.g., by ELISA. Assays using polyclonal or monoclonal antibodies specifically recognizing the said cardiac Troponins are in principle known in the art. Moreover, it is to be understood that a variant as referred to in accordance with the present invention shall have an amino acid sequence which differs due to at least one amino acid substitution, deletion and / or addition wherein the amino acid sequence of the variant is still at least 70%, preferably at least 80%, more preferably at least 85%, still more preferably at least 90%, even more preferably at least 92%, even more preferably at least 95%, even more preferably at least 97%, even more preferably at least 98%, most preferably at least 99%, identical with the amino sequence of the specific Troponin, preferably over the entire length. Variants may be allelic variants or any other species homologs, paralogs, or orthologs. Moreover, the variants referred to herein include fragments of the specific cardiac Troponins or the aforementioned types of variants as long as these fragments have the essential immunological and / or biological properties as referred to above. Preferably, the cardiac Troponin variants have immunological properties (i.e. epitope composition) comparable to those of human Troponin T or Troponin I. Thus, the variants shall be recognizable by the means or ligands used for determination of Troponins described elsewhere herein. Thus, the variants shall preferably be recognizable by the aforementioned means or ligands used for determination of the concentration of the cardiac Troponins described herein. Such fragments may be, e.g., degradation products of theUniversitat Heidelberg 16 UH17314PC

[0051] Troponins. Further included are variants which differ due to posttranslational modifications such as phosphorylation or myristylation. Preferably the biological property of Troponin I and its variants is the ability to inhibit actomyosin ATPase or to inhibit angiogenesis in vivo and in vitro, which may e.g. be detected based on the assay described by Moses et al. 1999 PNAS USA 96 (6): 2645. Preferably the biological property of Troponin T and its variant is the ability to form a complex with Troponin C and I, to bind calcium ions, and / or to bind to tropomyosin, preferably if present as a complex of Troponin C, I and T or a complex formed by Troponin C, Troponin I and a variant of Troponin T. It is known that low concentrations of circulating cardiac Troponin may be detected in subjects at various conditions (Masson et al., Curr Heart Fail Rep (2010) 7:15-21).

[0052] The cTn may be exosomal cTn or may be serum cTn. As referred to herein, the terms "exosomal cTn" and "serum cTn" relate to the compartment in which a cTn is detected and does not necessarily imply a structural difference, e.g. in folding or in amino acid sequence. Thus, exosomal cTn and serum cTn may as such be biochemically and / or immunologically indistinguishable, and may as such be indistinguishable for conventional assays used for determining cTns. Nonetheless, the aforesaid only applies to the exosomal cTn and serum cTn as such, since standard assays usually do not detect or only partially detect exosomal cTn, since it is enclosed in exosomes. As the skilled person understands in view of the description herein, the term "exosomal cTn" includes each and every cTn comprised in an exosome in a sample, wherein said sample is a sample in the state as taken from the subject, i.e. without any pretreatment. Correspondingly, the term "serum cTn", which may also be referred to as "free cTn" herein, includes each and every cTn comprised freely, i.e. not comprised in an exosome, in the aforesaid sample. Thus, the serum cTn preferably is the cTn detectable by standard assays in a sample without pretreatment destroying exosomes. In view of the above, the skilled person understands that the total cTn in a sample is the sum of serum cTn plus exosomal cTn, and that current standard cTn assays do not measure total cTn in a sample, but serum cTn. For the avoidance of doubt, determining an amount of an exosomal cTn comprises determining the amount only of cTn comprised in exosomes, so determining total cTn is not determining an amount of exosomal cTn. However, it is possible to calculate an amount of exosomal cTn as the difference between total cTn and serum cTn.

[0053] The term "exosome" is used herein in a broad sense including each and every extracellular vesicle comprised in a biological sample comprising at least one cellular constituent andUniversitat Heidelberg 17 UH17314PC

[0054] bounded by a lipid bilayer biological membrane. Preferably, the exosome has an essentially spherical structure with a preferred diameter in the range of from 10 nm to 500 nm, preferably 20 nm to 300 nm, more preferably 30 nm to 200 nm. Thus, as referred to herein, the term exosome does not necessarily imply any specific biological mechanism of exosome generation. Nonetheless, the exosome preferably is generated by budding of a late endosome, preferably followed by release of the exosome to the medium surrounding the exosome-producing cell. Preferably, the exosome is produced by a cell of the heart, preferably by subendocardial calls, more preferably by cells of the contractile apparatus.

[0055] Exosomes can be obtained from biological samples according to methods known in the art, e.g. by centrifugation, in particular differential centrifugation, filtration, size-exclusion chromatography, or any other method including size and / or density separation, such as biochemical density-based separation. Methods for extracting biomarkers, in particular polypeptide biomarkers, from exosomes are in principle known in the art and include in particular incubation with at least one detergent or other agent disrupting biological membrane bilayers, in particular Tris, Triton, or an intercalating agent such as saponin, and / or ultrasonication. Typically, extraction of polypeptide biomarkers from exosomes comprises incubation of exosomes under the aforesaid conditions for at least 2 hours, preferably at least 1 hour, more preferably at least 30 min, most preferably at most 10 min.

[0056] The term “sample”, as used herein, refers to a biological sample from a body fluid, preferably blood, plasma, serum, saliva or urine, or a sample derived from cells, tissues or organs, e.g., by biopsy. Preferably, the sample is a blood or a blood-derived sample, more preferably a serum or plasma sample, most preferably a serum sample. Even more preferably, the sample is a blood or plasma sample or is a serum or plasma sample. Preferably, the sample is a citrate plasma sample, a heparin plasma sample, or an EDTA plasma sample.

[0057] Biological samples can be derived from a subject by techniques known in the art. For example, blood samples may be obtained by blood taking, while tissue or organ samples are to be obtained, e.g., by biopsy. Preferably, the sample is known or suspected to comprise a biomarker referred to herein. The aforementioned samples may be pre-treated before they are used according to the present invention. Said pre-treatment may include treatments required to release or separate the biomarker(s) and / or the analyte(s) or to remove excessive material or waste. Suitable techniques comprise centrifugation, extraction, fractioning, ultrafiltration,Universitat Heidelberg 18 UH17314PC

[0058] protein precipitation followed by filtration and purification and / or enrichment of compounds. Moreover, other pre-treatments may be carried out in order to provide the biomarker and / or analyte in a form or concentration suitable for the intended determination. Suitable and necessary pre-treatments depend on the means used for carrying out the method of the invention and are well known to the person skilled in the art. Pre-treated samples as described before are also comprised by the term “sample” as used in accordance with the present invention.

[0059] The term “reference”, as used herein, relates to a value, e.g. an amount or any value derived therefrom, e.g. a score, which can be correlated to a medical condition and, preferably, which allows for the assessment as referred to herein to be made, more preferably enables allocation of a subject into either a group of subjects suffering from a disease or condition or being at risk for developing it, or a group of subjects which do not suffer from said disease or condition or which are not at risk for developing it. Such a reference can be a threshold value, e.g. a threshold amount, which separates these groups from each other. Accordingly, the reference may be a value, e.g. a threshold value, which allows for allocation of a subject into a group of subjects suffering from a disease or condition or being at risk for developing it, or not. For example, the reference may be a value which allows for allocation of a subject into a group of subjects suffering from heart disease, or being at risk of developing heart disease. The reference may, however, also be a reference range, e.g., preferably, a range of values for which heart disease may be assessed to be present in a subject. Furthermore, the reference may be a value calculated from the aforesaid values, e.g. from two or more biomarkers, preferably to provide a score, e.g. a predictor score as specified elsewhere herein. A suitable reference separating the two groups can be provided without further ado e.g. by the statistical tests referred to herein elsewhere based on values of biomarkers from suitable reference groups as specified herein below. As the skilled person understands, it may not always be possible, although preferred, to provide a reference unambiguously allocating each and every possible value of a biomarker to one of the aforesaid groups; thus, there may be a range of values for which a clear assessment cannot be provided. Preferably, however, as indicated above, a reference enables the assessment to be made for each and every value of a biomarker or set of biomarkers which may be measured. As the skilled person understands, the specific value of a reference may depend on the assessment intended and on parameters thereof; thus, e.g. the reference for a differential diagnosis between two subtypes of heart disease may be different from the reference for diagnosing heart disease and from the reference for predicting deterioration of heart disease. Relevant parameters having an influence on the reference may in particular be sensitivity and specificity of assessment.Universitat Heidelberg 19 UH17314PC

[0060] A reference may in particular be derived from at least one reference group, the term "reference group" relating to a group of subjects with known status with regard to the assessment. Thus, the reference group may e.g. be a group of subjects for which it is known whether they suffer from heart disease. The population of subjects in a reference group preferably comprises a plurality of subjects, e.g. at least 5, 10, 50, 100, 1,000, or 10,000 subjects. Typically, the subject to be diagnosed and the subjects of the said reference group are of the same species. The reference applicable for an individual subject may vary depending on various physiological parameters such as age, gender, or subpopulation. As is understood by the skilled person, in case prevalence of a disease in the population is low, e.g. at most 5%, preferably at most 1%, a reference may also be derived from the average population. Assuming that contribution of actually afflicted subjects is low, such an average population reference group may be treated as a reference group known not to suffer from heart disease; preferably, in such case, the size of the reference group is sufficiently high, e.g. at least 100, more preferably at least 1,000, even more preferably at least 10,000 subjects. In view of the description herein, the skilled person understands that a reference group may, in principle, also be a mixed population of subjects with regard to heart disease, provided that the status of each member of said mixed population in regard to heart disease is or becomes known before deriving a reference from such group. Also, a reference group may be a group of subjects known to suffer from the heart disease, preferably a subtype thereof. A reference may, however, also be obtained from the subject under investigation, if available, e.g. from a sample taken earlier in time, preferably before the onset of symptoms of heart disease.

[0061] Reference amounts can, in principle, be calculated for a cohort of subjects based on the average or mean values for a given parameter such as biomarker amount by applying standard statistically methods. In particular, accuracy of a test such as a method aiming to diagnose an event, or not, is best described by its receiver-operating characteristics (ROC) (see especially Zweig 1993, Clin. Chem. 39:561-577). The ROC graph is a plot of all of the sensitivity / specificity pairs resulting from continuously varying the decision threshold over the entire range of data observed. The clinical performance of a diagnostic method depends on its accuracy, i.e. its ability to correctly allocate subjects to a certain prognosis or diagnosis. The ROC plot indicates the overlap between the two distributions by plotting the sensitivity versus 1 -specificity for the complete range of thresholds suitable for making a distinction. On the y-axis is sensitivity, or the true-positive fraction, which is defined as the ratio of number of true-Universitat Heidelberg 20 UH17314PC

[0062] positive test results to the product of number of true-positive and number of false-negative test results. This has also been referred to as positivity in the presence of a disease or condition. It is calculated solely from the affected subgroup. On the x-axis is the false-positive fraction, or 1 -specificity, which is defined as the ratio of number of false-positive results to the product of number of true-negative and number of false-positive results. It is an index of specificity and is calculated entirely from the unaffected subgroup. Because the true- and false-positive fractions are calculated entirely separately, by using the test results from two different subgroups, the ROC plot is independent of the prevalence of the event in the cohort. Each point on the ROC plot represents a sensitivity / 1 -specificity pair corresponding to a particular decision threshold (i.e. reference). A test with perfect discrimination (no overlap in the two distributions of results) has a ROC plot that passes through the upper left comer, where the true-positive fraction is 1.0, or 100% (perfect sensitivity), and the false-positive fraction is 0 (perfect specificity). The theoretical plot for a test with no discrimination (identical distributions of results for the two groups) is a 45° diagonal line from the lower left corner to the upper right corner. Most plots fall in between these two extremes. If the ROC plot falls completely below the 45° diagonal, this is easily remedied by reversing the criterion for "positivity" from "greater than" to "less than" or vice versa. Qualitatively, the closer the plot is to the upper left comer, the higher the overall accuracy of the test. Dependent on a desired confidence interval, a threshold can be derived from the ROC curve allowing for the diagnosis or prediction for a given event with a proper balance of sensitivity and specificity, respectively. Accordingly, the reference to be used for the aforementioned method of the present invention, i.e. a threshold which allows to discriminate between subjects being at risk and not being at risk can be generated, usually, by establishing a ROC for said cohort as described above and deriving a threshold amount therefrom. Dependent on a desired sensitivity and specificity for a diagnostic method, the ROC plot allows deriving suitable thresholds. It will be understood that an optimal sensitivity may be desired for excluding a subject for being at increased risk (i.e. a rule-out), whereas an optimal specificity may be envisaged for a subject to be assessed as being at an increased risk (i.e. a rule-in).

[0063] The term “comparing” as used herein encompasses comparing a value, e.g. an amount, determined for a biomarker as referred to herein to a reference. It is to be understood that comparing as used herein refers to any kind of comparison made between the value for the amount with the reference. However, it is to be understood that preferably identical types of values are compared with each other, e.g., if an absolute amount is determined, the referenceUniversitat Heidelberg 21 UH17314PC

[0064] shall also be an absolute amount, if a relative amount is determined, the reference shall also be a relative amount, etc. The aforesaid comparison of identical types of values is also referred to a comparing to a "corresponding" value, e.g. a corresponding reference, herein. The term comparing also encompasses comparing a calculated score with a suitable reference score. Thus, preferably, the corresponding reference is a value of the quantitative parameter allowing the determination of step (c) to be made. Preferably, the reference is a reference predictor score obtained using a trainable model trained as described elsewhere herein.

[0065] The comparison may be carried out manually, computer assisted, or in a computer-implemented manner. The value determined and the reference can be, e.g., compared to each other and the said comparison can be automatically carried out by a computer program executing an algorithm for the comparison. The computer program carrying out the evaluation may provide the desired assessment in a suitable output format. As set forth above, it is also envisaged to calculate a score based on the amounts of more than one biomarker, which may also be referred to as "predictor score", in particular a single score, and to compare this score to a reference score. The calculated score preferably combines information on the amounts of the biomarkers. Moreover, in the score, the biomarkers may be weighted in accordance with their contribution to the establishment of the differentiation, wherein the weighting factor of the individual biomarkers may be different. The score can be regarded as a classifier parameter for the assessing as set forth herein. In particular, it enables providing the assessment based on a single score. Thus, the skilled person does not have to interpret the entire information on the amounts of the individual biomarkers. Using a scoring system as described herein, values of different dimensions or units for the biomarkers may be used since the values will be mathematically transformed into the score. Accordingly, e.g. values for absolute concentrations may be combined in a score with peak area ratios and / or enzymatic activity values. The reference score to be applied may be elected based on the desired sensitivity and / or the desired specificity. Preferably, the reference, in particular the reference score, is obtained by training at least one trainable model for assessing heart disease in a subject, as described herein below.

[0066] The method comprises step (a) determining an amount of a cardiac troponin (cTn) in exosomes (exosomal cTn) in a sample of a bodily fluid of a subject. Means and methods for determining biomarkers have been described elsewhere herein. According to step (a), the method comprises determining an amount of an exosomal cTn. Thus, further biomarkers may be determined, in particular further exosomal cTns, further cTns, such as at least one serum cTn, or other markersUniversitat Heidelberg 22 UH17314PC

[0067] known to be of value in the intended assessment. Moreover, as specified in more detail herein above, additional data may be obtained or determined, such as anamnesis data, and the like.

[0068] Determining in step (a) preferably comprises step (aa) contacting a solid support comprising a detection agent for the biomarker with a sample known or suspected to comprise the biomarker and (bb) measuring the amount of biomarker which is bound to the support. In such case, the detection agent is preferably present on a solid support in immobilized form, i.e. preferably is a capture agent.

[0069] Determining in step (a) preferably comprises the steps of (bbl) contacting the biomarker with a detection agent, (bb2) optionally removing non-bound detection agent, and (bb3) measuring the amount of bound detection agent, as the skilled person will understand, steps (bbl) to (bb3) may be performed without a preceding step (aa) as described herein above; such may e.g. the proceeding in an agglutination assay. Preferably, step (a) comprises steps (aa), (bbl), optional step (bb2), and step (bb3), such as e.g. in a sandwich immunoassay. However, step (a) may also only comprise step (aa), e.g. in an assay based on surface plasmon resonance measurements. Thus, in principle, the amount of a biomarker can be determined by determining a complex of the biomarker with at least one detection agent, in particular an antibody or fragment thereof, i.e. in an immunoassay. Said determining of a complex of the biomarker may be performed in any format deemed appropriate by the skilled person, in particular a sandwich, competition, or other assay format. Said assays will develop a signal which is indicative for the amount of a biomarker. Binding according to the present invention includes both covalent and non-covalent binding.

[0070] Preferably, the method comprises step (al) comparing the amount determined in step (a) to a first reference and / or calculating a score for assessing heart disease based on the amount determined in step (a). Methods for providing appropriate references and for calculating suitable scores are in principle known in the art and have been described herein above.

[0071] Also, preferably, the method comprises further step (a2) determining an amount of serum cTn in said sample. In such case, the method may further comprise step (a3) comparing the amount determined in step (a) to the amount determined in step (a2); thus, in particular the amount of exosomal cTn may be compared to the corresponding amount of serum cTn; i.e., in case e.g. exosomal cTnT is determined in step (a), serum cTnT is preferably determined in step (a2), andUniversitat Heidelberg 23 UH17314PC

[0072] the value obtained in step (a) for exosomal cTnT preferably is compared to the value determined in step (a2) for said serum cTnT. In addition or as an alternative, the method may also comprise step (a4) comparing the amount determined in step (a2) to a second reference and / or calculating a second score for assessing heart disease based on the amount determined in step (a2).

[0073] The cTn referred to herein may in particular be determined using Roche’s electrochemiluminescence ELISA sandwich test Elecsys Troponin T hs (high sensitive) assay, preferably as specified in the examples. The test is described in Giannitsis et al. (Giannitsis et al. 2009, Clin Chem. 56(2) 254-261). In particular, Giannitsis et al. describe an assay based on the Elecsys® / cobas e™ cTnT fourth-generation assay from Roche Diagnostics) on the Elecsys 2010 / cobas e 411 and Modular® Analytics E170 / cobas e 601 immunoanalyzers (Roche Diagnostics). The assay uses fragment antigen-binding (FAB) fragments of two cTnT specific mouse monoclonal antibodies in a sandwich format. The antibodies recognize epitopes located in the central part of the cTnT molecule (amino acid positions 125-131 and 135-147, respectively). Detection is based on an electrochemiluminescence immunoassay (ECLIA), using a Tris(bipyridyl)-ruthenium(II) complex as label.

[0074] The method comprises step (b) thereby assessing said heart disease. As the skilled person understands in view of the description herein, the step of thereby assessing heart disease may be an implicit result of the determining in step (a); i.e., a medical practitioner may be able to provide the desired assessment already when taking into account the result of step (a), optionally further taking into account further diagnostic information. Such may be e.g. the case in case the value determined in step (a) is very high or very low, such that an express comparison to a reference may be dispensable. Preferably, however, the method comprises further step (al) as described herein above. In particular in such case, also step (b) may be computer assisted or computer-implemented, e.g. on a processor of a system as described herein. Preferably, the method referred to herein is at least partially computer-implemented and at least step (b) is performed by a trained automated machine learning derived generalized logistic regression model, wherein said model preferably was trained as specified herein below.

[0075] As the skilled person understands in view of the description herein, the specific proceeding in step (b) may depend on the assessment which is intended. In case it shall be assessed whether a subject suffers from heart disease, it may be sufficient to determine an amount of exosomal cTn and, optionally, to compare said amount to a reference. In such case, an amount increasedUniversitat Heidelberg 24 UH17314PC

[0076] compared to a healthy reference, or equal to or increased compared to a reference of subjects known to suffer from heart disease, preferably leads to the assessment that the subject suffers from heart disease. In case a concomitant or discrete differentiation between a heart disease associated with myocardial strain, preferably atrial fibrillation, and a heart disease associated with myocardial ischemia, preferably myocardial infarction, is desired, it may be preferable to include steps (a2) and optionally (a3) in the method, i.e. to also determine an amount of serum cTn and optionally to compare the amount of exosomal cTn determined to the amount of serum cTn; e.g., a ratio of exosomal cTn to serum cTn may be calculated. As shown in the Examples provided herein, a value of exosomal cTn equal to cTn in exosome-depleted serum preferably is considered physiological, an exosomal cTn value of approximately 10% of the value of serum cTn indicates myocardial ischemia in the setting of acute myocardial infarction. Preferably, in heart diseases associated with myocardial strain, an exosomal cTn value in between physiological and ischemic states is found. Thus, preferably, a value of exosomal cTn equal to serum cTn is considered to be indicative of a subject not suffering from heart disease; an exosomal cTn value of about 10% or less of the value of serum cTn is indicative of a heart disease associated with myocardial ischemia, and an exosomal cTn value of from about 20% to 75% of the value of serum cTn is preferably indicative of a heart disease associated with myocardial strain. Also preferably, in case the ratio formed by dividing the amount of exosomal cTn by the amount of serum cTn is about 1, the subject is preferably deemed to not be suffering from heart disease, in case of a ratio of at most about 0.1, the subject is preferably deemed to suffer from a heart disease associated with myocardial ischemia, and in case of a ratio of from about 0.25 to about 0.75, the subject is preferably deemed to suffer from a heart disease associated with myocardial strain. As the skilled person understands in view of the description herein, the aforesaid ratio enables assessing heart disease without calibrating the method to measure absolute cTn amounts.

[0077] Optionally, the method comprises further step (aO) determining a number of exosomes in said sample. Methods for determining the number of exosomes in a sample are in principle known in the art and are described herein in the Examples. If step (aO) is performed, further steps of the method preferably are performed only in case the number of exosomes in said sample is increased compared to an exosome reference.

[0078] Advantageously, it was found in the work underlying the present invention that the biomarkers of the invention can also be detected in exosomes in particular of blood-derived samples, andUniversitat Heidelberg 25 UH17314PC

[0079] that the amounts of the biomarkers in exosomes, in particular in comparison to serum levels of the same biomarkers, are highly diagnostic in heart disease.

[0080] The definitions made above apply mutatis mutandis to the following. Additional definitions and explanations made further below also apply for all embodiments described in this specification mutatis mutandis.

[0081] The method of assessing heart disease described herein may be followed by a step of treating heart disease in the assessed subject, based on the assessment. Thus, the present invention also relates to a method for diagnosing and treating a heart disease, comprising (I) diagnosing said heart disease according to the method of assessing heart disease described herein, and (II) based on the diagnosing in step (I), treating heart disease in said subject.

[0082] The terms "treating" and “treatment” refer to an amelioration of the diseases or disorders referred to herein or the symptoms accompanied therewith to a significant extent. Said treating as used herein also includes an entire restoration of health with respect to the diseases or disorders referred to herein. It is to be understood that treating, as the term is used herein, may not be effective in all subjects to be treated. However, the term shall require that, preferably, a statistically significant portion of subjects suffering from a disease or disorder referred to herein can be successfully treated. Whether a portion is statistically significant can be determined without further ado by the person skilled in the art using various well-known statistic evaluation tools, as specified herein above. Treatments for heart disease are in principle known in the art.

[0083] Methods for treating heart diseases associated with myocardial strain include in particular methods described by relevant medical guidelines. In case the heart disease associated with myocardial strain is atrial fibrillation, treatment may comprise anti arrhythmic therapy, such as administration of beta adrenoceptor inhibitors, flecainide, propafenone, digitalis glycosides, dronedarone, venakalant, and / or amiodarone; and / or electrical cardioversion.

[0084] Therapeutic measures for subjects suffering from a heart disease associated with myocardial ischemia are known in the art as well, e.g., from relevant medical guidelines. In case the heart disease associated with myocardial ischemia is myocardial infarction, said therapeutic measure preferably is a cardiac intervention. The term “cardiac intervention”, preferably, encompasses those treatment regimens which comprise an intervention by surgery, microsurgery or otherUniversitat Heidelberg 26 UH17314PC

[0085] invasive therapies affecting the cardiovascular system and, preferably, the heart. Preferably, cardiac interventions as used herein are treatment regimens which aim to restore the proper oxygen supply of the heart. This is, preferably, achieved by restoring the blood flow throughout the blood vessels supporting the heart, i.e. the coronary blood vessels. Those blood vessels may be impaired due to, e.g., thrombotic or atherosclerotic plaques. Accordingly, cardiac interventions shall, preferably, comprise a destruction and / or removal of such plaques and a restoration of the vessel, if necessary. Preferred cardiac interventions in accordance with the present invention are selected from the group consisting of percutaneous coronary angioplasty, percutaneous transluminal coronary balloon angioplasty, laser angioplasty, coronary stent implantation, bypass implantation or intraluminal techniques aiming to restore blood flow, vessel patency, stabilize plaque, and / or reduce intracoronary thrombus load.

[0086] Some or all steps of the methods described herein may be computer-assisted or computer-implemented. Thus, the present invention also relates to a computer-implemented method for assessing a heart disease in a subject, said method comprising

[0087] (A) obtaining an amount of exosomal cTn in a sample of a bodily fluid of said subject;

[0088] (B) comparing the amount of the exosomal cTn obtained in step (A) to a first reference and / or calculating a score for assessing heart disease based on the amount determined in step (A); and (C) assessing heart disease in said subject based on the comparison and / or the calculation made in step (B).

[0089] The invention further discloses and proposes a computer program product having program code means, in order to perform the method according to the present invention in one or more of the embodiments enclosed herein when the program is executed on a computer or computer network. Specifically, the program code means may be stored on a computer-readable data carrier.

[0090] Further, the invention discloses and proposes a data carrier having a data structure stored thereon, which, after loading into a computer or computer network, such as into a working memory or main memory of the computer or computer network, may execute the method according to one or more of the embodiments disclosed herein.

[0091] The invention further proposes and discloses a computer program product with program code means stored on a machine-readable carrier, in order to perform the method according to oneUniversitat Heidelberg 27 UH17314PC

[0092] or more of the embodiments disclosed herein, when the program is executed on a computer or computer network. As used herein, a computer program product refers to the program as a tradable product. The product may generally exist in an arbitrary format, such as in a paper format, or on a computer-readable data carrier. Specifically, the computer program product may be distributed over a data network.

[0093] Finally, the invention proposes and discloses a modulated data signal which contains instructions readable by a computer system or computer network, for performing the method according to one or more of the embodiments disclosed herein.

[0094] Preferably, referring to the computer-implemented aspects of the invention, one or more of the method steps or even all of the method steps of the method according to one or more of the embodiments disclosed herein may be performed by using a computer or computer network. Thus, generally, any of the method steps including provision and / or manipulation of data may be performed by using a computer or computer network. Generally, these method steps may include any of the method steps, typically except for method steps requiring manual work, such as providing the samples and / or certain aspects of performing the actual measurements.

[0095] Specifically, the present invention further discloses:

[0096] A computer or computer network comprising at least one processor, wherein the processor is adapted to perform the method according to one of the embodiments described in this description,

[0097] a computer loadable data structure that is adapted to perform the method according to one of the embodiments described in this description while the data structure is being executed on a computer,

[0098] a computer program, wherein the computer program is adapted to perform the method according to one of the embodiments described in this description while the program is being executed on a computer,

[0099] a computer program comprising program means for performing the method according to one of the embodiments described in this description while the computer program is being executed on a computer or on a computer network,

[0100] a computer program comprising program means according to the preceding embodiment, wherein the program means are stored on a storage medium readable to a computer, a storage medium, wherein a data structure is stored on the storage medium and wherein theUniversitat Heidelberg 28 UH17314PC

[0101] data structure is adapted to perform the method according to one of the embodiments described in this description after having been loaded into a main and / or working storage of a computer or of a computer network, and

[0102] a computer program product having program code means, wherein the program code means can be stored or are stored on a storage medium, for performing the method according to one of the embodiments described in this description, if the program code means are executed on a computer or on a computer network.

[0103] The computer-implemented method for assessing a heart disease comprises step (A) obtaining an amount of exosomal cTn in a sample of a bodily fluid of said subject. The term "obtaining", as used herein, relates to acquiring the indicated information, in particular a value of a parameter such as an amount of a biomarker, in a manner enabling basing the assessment on said information. Thus, preferably, obtaining is reading the information from a data carrier, e.g. in the form of a data sheet, of an analysis device output, e.g. a result of an immunoassay or a mass spectrometry measurement, or the like; or from a database comprising at least the relevant information. Preferably, the information obtained comprises an amount of a biomarker determined as specified herein above. The data carrier and / or the database may be local, i.e. physically connected to a device used to perform steps of the method; they may, however, also be remote, accessible via a network connection or via the internet; thus, the data carrier and / or the data carrier may e.g. be cloud storage. Also, the method may be implemented as a service provided by means of a network connection, e.g. via internet, in which values of the biomarkers, or one or more score(s) derived therefrom, are obtained from e.g. a device performing the determination or medical practitioner, and the result of the comparison is output. Preferably, obtaining an amount of exosomal cTn is determining said amount, preferably as specified herein above for step (a) of the method for assessing a heart disease. Further step (B) preferably corresponds to step (al), and step (C) preferably corresponds to step (b), both of the method for assessing a heart disease.

[0104] The present invention also relates to a database comprising stored references for amounts of exosomal cTn for assessing heart disease. The term “database”, as used herein, refers to a collection of data which may be physically and / or logically grouped together and which are, preferably, tangibly embedded on a storage means. Accordingly, the database preferably comprises an allocation of references to assessment results. As the skilled person understands from the description herein above, "stored references for amounts of exosomal cTn" may alsoUniversitat Heidelberg 29 UH17314PC

[0105] be one or more scores derived from said references. The database, preferably, comprises further data, such as upper and / or lower detection limits, references for further biomarkers, in particular those described herein above, data relevant for plausibility checks, and the like. More preferably, the database comprises data on one or more assay methods to use, lot-specific data, e.g. for calibrator samples, and the like. Preferably, the database may be implemented in a single data storage medium or in physically separated data storage media being operatively linked to each other. Preferably, the database comprises a data collection on a suitable storage medium, preferably tangible embedded thereon. Moreover, the database, preferably, further comprises a database management system. The database management system is, preferably, a networkbased, hierarchical or object-oriented database management system. Furthermore, the database may be a federal or integrated database. More preferably, the database will be implemented as a distributed (federal) system, e.g. as a Client-Server-System. Also preferably, the database is structured as to allow a search algorithm to compare a test data set with the data sets, in particular the references, comprised by the data collection. Specifically, by using such an algorithm, the database can be searched for similar or identical data sets being indicative for a medical condition or effect as set forth above (e.g. a query search). Thus, preferably, if data set fulfilling the comparison criteria as detailed elsewhere herein can be identified in the database, the test data set will be associated with the said medical condition or effect. Consequently, the information obtained from the database can be used, e.g., as a reference for the methods described elsewhere herein.

[0106] The methods of the present invention may also be performed using a system having the appropriate means for performing at least one step of such a method. Thus, the present invention also relates to a system comprising an evaluation device with a data processor, the evaluation device comprising instructions for providing an assessment of a heart disease based on an amount of exosomal cTn obtained by the evaluation device.

[0107] The term “system”, as used herein, relates to a combination of means comprising the aforementioned units operatively linked to each other to allow obtaining the amount of a biomarker and evaluation thereof according to a method as specified herein such that an assessment can be provided. Preferably, the assessing by the system is carried out according to a method as described herein above. Preferably, said assessing is carried out by the evaluation device by carrying out a comparison of the amount of the exosomal cTn to a first reference and / or for carrying out a calculation of a score for assessing based on the amounts of theUniversitat Heidelberg 30 UH17314PC

[0108] exosomal cTn. Preferably, said comparison and / or said calculation is performed according to a method described elsewhere herein, in particular the computer-implemented method for assessing a heart disease.

[0109] The evaluation device comprises at least one data processor, which may also be referred to as a data processing unit, such as a computer, with an implemented algorithm for determining the amount present in the sample. Appropriate data processing units are known in the art and include in particular a Central Processing Unit (CPU), a Graphics Processing Units (GPU), an Application Specific Integrated Circuit (ASIC), a Tensor Processing Unit (TPU), a field-programmable gate array (FPGA), and other data processing units know in the art. A data processor may e.g. be a general purpose computer or a portable computing system. It should also be understood that multiple computing systems may be used together, such as over a network or other methods of transferring data, for performing one or more steps of the methods disclosed herein. Exemplary computing systems include desktop computers, laptop computers, personal data assistants (“PDA”), cellular systems, smart or mobile systems, tablet computers, servers, and the like. In general, a data processing unit comprises a processor capable of executing a plurality of instructions (such as a program of software).

[0110] The evaluation device typically comprises or has access to a memory. A memory is a computer readable information storage medium and may comprise a single storage system or multiple storage systems, located either locally with the computing system or accessible to the computing system across a network, for example. Computer-readable media may be any available media that can be accessed by the computing system and includes both volatile and non-volatile media. Further, computer readable-media may be one or both of removable and non-removable media. By way of example, and not limitation, computer-readable media may comprise computer storage media. Exemplary computer storage media includes, but is not limited to, RAM, ROM, EEPROM, flash memory or any other memory technology, CD-ROM, Digital Versatile Disk (DVD) or other optical disk storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage systems, or any other medium which can be used for storing a plurality of instructions capable of being accessed by the computing system and executed by the processor of the computing system. The evaluation device, preferably, further comprises a database as specified herein above.

[0111] According to embodiments of the instant disclosure, software may include instructions which,Universitat Heidelberg 31 UH17314PC

[0112] when executed by a processor of the computing system, may perform one or more steps of the methods disclosed herein. Some of the instructions may be adapted to produce signals that control operation of other units of the system, e.g. a measuring unit and / or other systems and thus may operate through those control signals to transform materials far removed from the system itself. These descriptions and representations are the means used by those skilled in the art of data processing, for example, to most effectively convey the substance of their work to others skilled in the art.

[0113] The plurality of instructions may also comprise an algorithm which is generally conceived to be a self-consi stent sequence of steps leading to a desired result. These steps may include those requiring physical manipulations of physical quantities. Usually, though not necessarily, these quantities take the form of electrical or magnetic pulses or signals capable of being stored, transferred, transformed, combined, compared, and otherwise manipulated. It proves convenient at times, principally for reasons of common usage, to refer to these signals as values, characters, display data, numbers, or the like as a reference to the physical items or manifestations in which such signals are embodied or expressed. It should be borne in mind, however, that all of these and similar terms are to be associated with the appropriate physical quantities and are merely used here as convenient labels applied to these quantities.

[0114] The evaluation device may also comprise or have access to an output device. Exemplary output devices include displays, printers, files, and telecommunication systems, such as fax systems, data servers, and the like. According to some embodiments, a computing system may perform one or more steps of a method disclosed herein, and thereafter provide an output, via an output device, relating to an assessment result, indication, ratio or other factor of the method. The evaluation device may also comprise or have access to an input device, such as a keyboard, a data reader, a data connection to an analytic device, or any other input device deemed appropriate by the skilled person.

[0115] The system may further comprise, operatively connected to the processor, an analytic device configured for determining said exosomal cTn in said sample. The analytic device, typically, comprises at least one reaction zone having a detection agent for the biomarker. The device may comprise one or more further detection agent(s) for one or more further, optional biomarker(s). The detection agent may be comprised in immobilized form on a solid support or carrier which is to be contacted to the sample. The detection agent may, however, also beUniversitat Heidelberg 32 UH17314PC

[0116] comprised e.g. in liquid form in the device, e.g. as a stock solution. Moreover, in the reaction zone, it is preferably possible to apply conditions which allow for the specific binding of the detection agent(s) to the biomarker comprised in the sample and / or for a catalytic reaction to occur. The reaction zone may either allow directly for sample application or it may be connected to a loading zone where the sample is applied. In the latter case, the sample can be actively or passively transported via a connection between the loading zone and the reaction zone to the reaction zone. Moreover, the reaction zone shall preferably be connected to a detection means, which, may also be referred to as a "detector". The connection shall be such that the detector can detect the result of a detection reaction, e.g. the binding of the biomarker to its detection agent(s) or an enzymatic reaction. Suitable detectors depend on the techniques used for measuring the presence or amount of the biomarkers. For example, for optical detection, transmission of light may be required between the detector and the reaction zone while for electrochemical determination a fluid connection may be required, e.g., between the reaction zone and an electrode. The detector shall be adapted to allow determination of the amount of the biomarker(s). The determined amount can be subsequently transmitted to the evaluation unit.

[0117] Some components suitable for performing the methods described herein may also be provided as a kit. Thus, the present invention also relates to a kit for assessing heart disease in a subject comprising a detection agent for determining an amount of a cTn and an agent liberating cTn from exosomes

[0118] The term “kit” as used herein refers to a collection of the aforementioned components, typically, provided in separate compound(s) or as a mixture of compounds. The means are, preferably, provided in a single container (i.e. a housing), more preferably enabling common translocation, e.g. transport, of the components. The container also typically comprises instructions for carrying out the method of the present invention. These instructions may be in the form of a manual or may be provided by a computer program code which is capable of carrying out or supports the determination of the biomarkers referred to in the methods of the present invention when implemented on a computer or a data processing system. The computer program code may be provided on a data storage medium or system such as an optical storage medium (e.g., a Compact Disc) or directly on a computer or data processing system or may be provided in a download format such as a link to an accessible server or cloud. Moreover, the kit may, usually, comprise standards for reference amounts of biomarkers for calibration purposes. The kit mayUniversitat Heidelberg 33 UH17314PC

[0119] also comprise further components which are necessary for carrying out a method described herein, may assist in doing so, or may provide further functions; preferably, the further component is a solvent, a buffer, a diluent, a washing solution and / or one or more reagent(s) required for detection of a biomarker.

[0120] The present invention also relates to a use of an amount of an exosomal cTn for assessing heart disease, wherein said use is an in vivo use or an in vitro use.

[0121] In a preferred embodiment, the present invention also relates to a method for determining an amount of a total cTn in a sample of a subject, the method comprising

[0122] (i) contacting said sample with a chemical means and / or a physical means for lysing exosomes, (ii) determining an amount of a cTn in the sample obtained in step (i), and, thereby

[0123] (iii) determining the amount of a total cTn in said sample.

[0124] The term "total cTn" has been specified herein above and preferably relates to the sum amount of cTn in a sample, irrespective of whether it is free cTn or is compartmentalized, e.g. in exosomes. For clarity, the term "amount of a total cTn" preferably does not relate to a sum amount over different cTn species, e.g. cTnT and cTnl, but refers to the sum amount of one species, preferably cTnT or cTnl, in a sample. It is, however, in principle, also possible to determine the total amount of more than one species of cTn, e.g. of cTnT and cTnl. As the skilled person understands, whether cTnT and / or cTnl is determined is preferably dictated by the downstream determination method, not by the contacting in step (i). In the context of the method for determining an amount of a total cTn, the sample used in step (i) preferably is a cell-free sample, more preferably is a serum or plasma sample.

[0125] In a preferred embodiment, the term "chemical means" for lysing exosomes includes each and every chemical means deemed appropriate by the skilled person for the indicated purpose. Chemical means for lysing exosomes are in principle known to the skilled person, e.g. from Romano & Cinti (2023), ChemRXIV, doi.org / 10.26434 / chemrxiv-2023-fhll7. Thus, chemical means preferably include detergents, preferably a Triton, sodium dodecyl sulfate (SDS), NP-40, a saponin, Tween-20, and / or 4-hexylphenylazosulfonate; include chaotropic agents, preferably urea and / or guanidine-containing compounds; and include solvents, preferably methanol and / or Trizol. Chemical means are preferably used at concentrations and under conditions usual in the art and are known e.g. from Romano & Cinti (2023) (loc.cit). Preferably, the chemical meansUniversitat Heidelberg 34 UH17314PC

[0126] is a Triton, more preferably a Triton X, most preferably Triton X-100, and preferably is used at a concentration of from 0.01% (v / v) to 10% (v / v) in the lysis admixture of step (i), more preferably at a concentration of from 0.05 (v / v) to 5% (v / v), most preferably of from 0.1% (v / v) to 1%.

[0127] In a preferred embodiment, the term "physical means" for lysing exosomes includes each and every physical means deemed appropriate by the skilled person for the indicated purpose. Preferably, the physical means is a mechanical means, preferably an ultrasonication, an application of shearing forces, and / or an application of a pressure gradient treatment ("french press"). More preferably, the physical means is ultrasonication, more preferably low-intensity ultrasonication performed at a frequency of 20-40 kHz. Preferably, ultrasonication is performed for 1 to 25 cycles, more preferably for from 2 to 10 cycles, more preferably for 3, 4, 5, 6, 7, 8, or 9 cycles, even more preferably for 4, 5, or 6 cycles, most preferably for 5 cycles, wherein each cycle has a duration of 5 s to 120 s, preferably 10 s to 90 s, more preferably from 20 s to 60 s, still more preferably about 30 s, most preferably 30 s.

[0128] In a preferred embodiment, step (i) comprises further treatments. Preferably, the sample is further contacted with at least one protease inhibitor in step (i). Also, the contacting in step (i) preferably is followed by centrifugation of the sample admixture before proceeding to step (ii). Preferably, in said centrifugation, non-soluble sample constituents, e.g. membrane fragments of exosomes, biological polymers denatured by the contacting step, and the like, are removed. Thus, the centrifugation preferably is performed for from 1 min to 60 min, preferably from 2 min to 30 min, more preferably from 3 min to 10 min, even more preferably about 5 min, most preferably for 5 min, at from 1000 g to 15000 g, preferably from 5000 g to 10000 g, more preferably from 7000 g to 9000 g, even more preferably at about 8000 g, most preferably at 8000 g.

[0129] In a preferred embodiment, the present invention also relates to a method for assessing a heart disease in a subject, the method comprising the steps of the method for determining an amount of a total cTn in a sample of a subject as described herein above, and thereby assessing said heart disease.

[0130] The aforesaid method, in a preferred embodiment, increases analytical sensitivity, specificity, precision and / or accuracy of cTn assays; preferably increases the clinical sensitivity andUniversitat Heidelberg 35 UH17314PC

[0131] specificity of cTn assays, more preferably allows for earlier detection of evolving myocardial infarction, for discrimination of different forms of myocardial injury, preferably including structural heart disease, for improved monitoring of disease or treatment for earlier and more accurate detection of myocardial injury, preferably heart failure, myocarditis, amyloidosis, and / or cancer therapy-related myocardial injury. The method preferably further allows for improvement of short-term, mid-term, and / or long-term prognostication of cardiovascular disease with total cardiac troponin readout, in particular with respect to conditions including acute or chronic coronary syndrome, acute or chronic heart failure, and / or early onset structural heart disease in overtly healthy individuals.

[0132] As the skilled person understands in view of the description herein, the method for assessing a heart disease in a subject comprising determining an amount of a total cTn in a sample of a subject in a preferred embodiment is combined with the method for assessing a heart disease in a subject comprising determining an amount of an exosomal cTn as specified herein. From such a combination, the total cTn and the exosomal cTn are preferably obtained, and the amount of free cTn, if desired, can be calculated by subtracting the amount of exosomal cTn from the amount of total cTn.

[0133] Summarizing the findings of the present invention, the following embodiments are particularly envisaged:

[0134] Embodiment 1: A method for assessing a heart disease in a subject, the method comprising

[0135] (a) determining an amount of a cardiac troponin (cTn) in exosomes (exosomal cTn) in a sample of a bodily fluid of said subject; and

[0136] (b) thereby assessing said heart disease.

[0137] Embodiment 2: The method of claim 1, wherein said method further comprises step (al) comparing the amount determined in step (a) to a first reference and / or calculating a score for assessing heart disease based on the amount determined in step (a).

[0138] Embodiment s: The method of claim 1 or 2, wherein said sample is a blood-derived sample.

[0139] Embodiment 4: The method of any one of embodiment 1 to 3, wherein said sample is a serum, plasma, or blood sample.Universitat Heidelberg 36 UH17314PC

[0140] Embodiment 5: The method of any one of embodiment 1 to 4, wherein said sample is a cell-free sample

[0141] Embodiment 6: The method of any one of embodiment 1 to 5, wherein said sample is a serum sample.

[0142] Embodiment 7: The method of any one of embodiment 3 to 6, wherein said method further comprises step (a2) determining an amount of serum cTn in said sample.

[0143] Embodiment 8: The method of any claim 7, wherein said method further comprises step (a3) comparing the amount determined in step (a) to the amount determined in step (a2).

[0144] Embodiment 9: The method of 7 or 8, wherein said method further comprises step (a4) comparing the amount determined in step (a2) to a second reference and / or calculating a second score for assessing heart disease based on the amount determined in step (a2).

[0145] Embodiment 10: The method of any one of embodiment 1 to 9, wherein assessing heart disease is differentiating between a heart disease associated with myocardial strain and a heart disease associated with myocardial ischemia.

[0146] Embodiment 11 : The method of any one of embodiment 1 to 10, wherein said heart disease associated with myocardial strain is an atrial fibrillation and / or wherein said heart disease associated with myocardial ischemia is a myocardial infarction.

[0147] Embodiment 12: The method of any one of embodiment 1 to 11, wherein assessing heart disease is providing data aiding in diagnosing heart disease, is excluding heart disease, is excluding at least one type of heart disease, is providing information aiding a decision on further diagnostic and / or treatment steps, or is diagnosing heart disease.

[0148] Embodiment 13: The method of any one of embodiment 1 to 12, wherein a value of a ratio of the amount of exosomal cTn divided by the amount of serum cTn being about 1 is indicative of a subject not suffering from heart disease, a value of said ratio of at most about 0.1 is indicative of a subject suffering from a heart disease associated with myocardial ischemia, and a value of said ratio of from about 0.25 to about 0.75 is indicative of a subject suffering from a heart disease associated with myocardial strain.

[0149] Embodiment 14: The method of any one of embodiment 1 to 13, wherein said subject shows or showed symptoms of a heart disease, preferably at the time said sample was obtained. Embodiment 15: The method of any one of embodiment 1 to 14, wherein said first reference is an amount of said exosomal cTn in an earlier blood-derived sample of said subject taken before the onset of said symptoms, and wherein an increase of exosomal cTn relative said earlier sample is indicative of a heart disease associated with myocardial strain.

[0150] Embodiment 16: The method of any one of embodiment 1 to 15, wherein assessing heartUniversitat Heidelberg UH17314PC

[0151] disease is assessing arrhythmia.

[0152] Embodiment 17: The method of any one of embodiment 1 to 16, wherein assessing heart disease is assessing myocardial infarction.

[0153] Embodiment 18: The method of any one of embodiment 1 to 17, wherein said subject is a mammal.

[0154] Embodiment 19: The method of any one of embodiment 1 to 18, wherein said subject is a human.

[0155] Embodiment 20: The method of any one of embodiment 1 to 19, wherein said method comprises further step (aO) determining a number of exosomes in said sample and wherein further steps of the method are performed only in case the number of exosomes in said sample is increased compared to an exosome reference.

[0156] Embodiment 21: The method of any one of embodiment 1 to 20, wherein said exosomal cTn is cTn comprised in exosomes in said sample.

[0157] Embodiment 22: The method of any one of embodiment 7 to 17, wherein said serum cTn is free cTn not comprised in exosomes.

[0158] Embodiment 23 : The method of any one of embodiment 1 to 22, wherein said heart disease is myocardial disease or is myocardial infarction.

[0159] Embodiment 24: The method of any one of embodiment 1 to 23, wherein said cTn is cardiac troponin T (cTnT) and / or cardiac Troponin I (cTnl).

[0160] Embodiment 25: A method for diagnosing and treating a heart disease, comprising (I) diagnosing said heart disease according to the method of any one of embodiment 1 to 24, and

[0161] (II) based on the diagnosing in step (I), treating heart disease in said subject.

[0162] Embodiment 26: The method of claim 25, wherein said treating said heart disease comprises cardiac catheterization, medical therapy, and / or electric cardioversion.

[0163] Embodiment 27: A computer-implemented method for assessing a heart disease in a subject, said method comprising

[0164] (A) obtaining an amount of exosomal cTn in a sample of a bodily fluid of said subject; (B) comparing the amount of the exosomal cTn obtained in step (A) to a first reference and / or calculating a score for assessing heart disease based on the amount determined in step (A); and

[0165] (C) assessing heart disease in said subject based on the comparison and / or the calculation made in step (B).

[0166] Embodiment 28: A database comprising stored references for amounts of exosomal cTnUniversitat Heidelberg 38 UH17314PC

[0167] for assessing heart disease.

[0168] Embodiment 29: The database of claim 28, wherein said database is tangibly embedded on a storage means.

[0169] Embodiment 30: A system comprising an evaluation device with a data processor, the evaluation device comprising instructions for providing an assessment of a heart disease based on an amount of exosomal cTn obtained by the evaluation device.

[0170] Embodiment 31 : The system of claim 30, wherein said comparison and / or said calculation is performed according to the method according to any one of embodiments 1 to 26.

[0171] Embodiment 32: The system of claim 31, wherein said determining is obtaining said amount, preferably from a database or a memory unit.

[0172] Embodiment 33: The system of any one of embodiment 30 to 32, further comprising at least one of an output device and an input device.

[0173] Embodiment 34: The system of any one of claims 30 to 33, further comprising, operatively connected to the processor, an analytic device configured for determining said exosomal cTn in said sample.

[0174] Embodiment 35: The system of any one of claims 30 to 36, wherein said analytic device comprises at least one detection means for said exosomal cTn.

[0175] Embodiment 36: The device of claim 30, wherein said detection means is capable of specifically detecting at least one cTn.

[0176] Embodiment 37: The device of claim 30 or 31, wherein said detection means is capable of specifically detecting said cTn in exosomes.

[0177] Embodiment 38: A kit for assessing heart disease in a subject comprising a detection agent for determining an amount of a cTn and an agent liberating cTn from exosomes.

[0178] Embodiment 39: Use of an amount of an exosomal cTn for assessing heart disease.

[0179] Embodiment 40: A method for determining an amount of a total cTn in a sample of a subject, the method comprising

[0180] (i) contacting said sample with a chemical means and / or a physical means for lysing exosomes, (ii) determining an amount of a cTn in the sample obtained in step (i), and, thereby

[0181] (iii) determining the amount of a total cTn in said sample.

[0182] Embodiment 41: The method of embodiment 40, wherein step (i) comprises contacting said sample with a chemical means and a physical means for lysing exosomes.

[0183] Embodiment 42: The method of embodiment 40 or 41, wherein said chemical means is a detergent, preferably a Triton, more preferably Triton-XIOO.

[0184] Embodiment 43 : The method of any one of embodiments 40 to 42, wherein said physicalUniversitat Heidelberg 39 UH17314PC

[0185] means is ultrasonication, preferably low-intensity ultrasonication.

[0186] Embodiment 44: A method for assessing a heart disease in a subject, the method comprising the steps of the method for determining an amount of a total cTn in a sample of a subject of any one of embodiments 40 to 42, and thereby assessing said heart disease

[0187] All references cited in this specification are herewith incorporated by reference with respect to their entire disclosure content and the disclosure content specifically mentioned in this specification.

[0188] Figure Legends

[0189] Fig. 1: Hypoxia triggers exosomal bound troponin T release in vitro. A Rat H9c2 myoblasts differentiated into a cardiomyocyte-like phenotype in the presence of all-trans-retinoic acid (ATRA) were exposed to incremental duration of hypoxia at 1% atmospheric O2. B Hypoxic conditions trigger cardiac troponin T (cTnT) expression in H9c2 cells. C Under hypoxia, exosomes released by differentiated H9c2 cells are increasingly enriched with cTnT as detected by high-sensitive cTnT pulldown. D Transfection of TNNT2-His or Luciferase control plasmid to differentiated H2c9 cardiomyocyte-like cells reveals progressive granulation of His-tagged cTnT under hypoxic stress.

[0190] Fig. 2: Stimulation of early-onset exosome release into circulation is observed following minimal invasive myocardial infarction (MiMi) in mice. A Schematic of in vivo experiment: wild type mice between 18 and 21 weeks of age are exposed to either MiMi or sham operation. After 4 hours of ischemia, mice are euthanized and serum is obtained from terminal blood draw for exosome isolation. Whole hearts are harvested for histologic analysis. B Masson Trichrome staining of whole heart sections reveals early signs of ischemia in the anterior segments following LAD coagulation. In sham mice, no signs of ischemic myocardium were appreciated.

[0191] C Free serum cTnT measurements reveal a consecutive increase in cTnT in MiMi mice compared to sham. D Representative images from nanoparticle tracking analysis of serum exosome isolates demonstrate a marked increase in circulatory exosomes 4 hours after MiMi compared to sham operation. E Quantitative nanoparticle tracking shows an increase in serum exosomes 4 hours after MiMi compared to sham, while no significant difference in exosome size was observed.Universitat Heidelberg 40 UH17314PC

[0192] Fig. 3: Induction of tachyarrhythmia in a porcine model of atrial fibrillation induces systemic exosome release concomitant with a shift in relative exosomal cTnT fraction. A Schematic of experiment with pacing-induced tachyarrhythmia over 5 days. B Increase in total serum cTnT after 5 days of arrhythmia-induced strain. C Nanoparticle tracking of serum exosomal isolates to quantify exosome concentration and D average exosome size at day 0 baseline and after 5 days of tachyarrhythmia. E Relative exosomal-fraction cTnT (left) and cTnT in exosome-depleted serum (right) compared to total serum cTnT at baseline and day 5.

[0193] Fig. 4: Analysis of serum samples from patients with myocardial ischemia (NSTEMI) and arrhythmia-induced myocardial strain (Afib / Aflut) recapitulates quantitative exosome release and exosomal troponin signatures. A Total exosome concentration in serum is significantly increased in patients with NSTEMI and Afib compared to healthy controls. B Nanoparticle tracking shows no significant difference in exosome size between experimental groups. C High-sensitive cTnT immunoprecipitation of exosomal isolates and depleted serum of control and NSTEMI patients shows differential cTnT enrichment in serum and exosomal compartments dependent on myocardial ischemia. D Relative concentration of exosomal cTnT compared to free serum cTnT reveals disease-specific patterns, showing equal compartmentalization of cTnT in free serum and exosomes in cardiac homeostasis, whilst in ischemia and strain states, a shift towards free serum cTnT is observed. Exosome-depleted cTnT is equivalent to total measured cTnT. E Relative concentration of exosomal cardiac troponin I (cTnl) using a high-sensitive assay, under cardiac homeostasis and myocardial strain, cTnl was found to be enriched in serum exosomes, whilst in the setting of myocardial ischemia, a shift towards free serum cTnl was observed, congruent with cTnT compartmentalization.

[0194] Fig. 5: (A) Case schematic on differential cardiac troponin assessment from a single blood draw, with standard quantification of free cTn fraction only vs. total cTn by modified assay.

[0195] (B) Schematic of rapid total cTn assay, liberating exosomal cTn fraction through combined lysis in a matter of minutes.

[0196] Fig. 6: (A) Relative total serum cTnT to native serum cTnT in patients with NSTEMI over the first 96 hours following first presentation to the Chest Pain Unit. (B) Relative total serum cTnT to native serum cTnT in patients with NSTEMI (left), showing a highly significant, 19% average increase post exosomal cTnT liberation, and recombinant cTnT spike-in control serum vs. NSTEMI following exosomal cTn liberation (right), (C) Relative total serum cTnT to nativeUniversitat Heidelberg 41 UH17314PC

[0197] serum cTnT following exosomal lysis with 5’, 30’ and 60’ incubation, (D) 0.1% vs. 1% lysis agent concentration, and (E) low-intensity vs. high-intensity ultrasonication. Results in C-E show no additional lysis effect upon modification of exosomal lysis conditions.

[0198] The following Examples shall merely illustrate the invention. They shall not be construed, whatsoever, to limit the scope of the invention.

[0199] Example 1: Methods for EV isolation

[0200] 1.1 Method

[0201] We established a workflow for a time-efficient and highly reproducible isolation of exosomes from fresh serum samples of patients presenting to the emergency department (Chest Pain Unit) at University Hospital Heidelberg, paired with state-of-the-art quantification of exosomal cTnT through high-sensitive assays and downstream characterization of serum exosome release by nanoparticle tracking. According to MISEV guidelines, four complementary methods should be used to quantitatively and qualitatively characterize isolated EV using the starting material as control, among which are 1) light scattering methods such as dynamic light scattering (DLS) or nanoparticle tracking analysis (NTA), 2) demonstration of at least three EV-specific surface and intraluminal markers (e.g. CD9, CD63, CD81 or HSC70), 3) detection of co-isolated potential contaminant entities such as lipoproteins, and 4) EV visualization using a microscopic imaging technique such as transmission electron microscopy.

[0202] 1.2 PB-EV isolation

[0203] Citrated venous blood samples were obtained from routine phlebotomy and processed within 120 minutes, avoiding agitation. Whole blood samples were diluted in ice-cold phosphate buffered saline (PBS) to reduce viscosity, and serum was separated through density gradient centrifugation. Using incremental centrifugation steps to remove cellular and subcellular debris and apoptotic bodies, with a final ultracentrifugation step, exosomes were pelleted and exosome-depleted supernatant was removed and stored at -80°C. Exosomes were resuspended according to downstream analysis and either processed immediately or stored at -80°C until further use.

[0204] 1.3 Nanoparticle tracking analysis

[0205] Exosomal isolates were used for quantification using nanoparticle tracking analysis. A suitable working solution was determined empirically to achieve a particle concentration withinUniversitat Heidelberg 42 UH17314PC

[0206] detection limits to maximize reproducibility. Diluted exosomal samples were analyzed using a Nanosight NS300 with constant camera setting and detection threshold throughout measurements, and nanoparticle concentration and size distribution was quantified in a standardized manner across all samples.

[0207] 1.4 Fractional cTnT quantification

[0208] Exosomal cTnT levels were quantified using resuspended exosomal pellets in radioimmunoprecipitation assay buffer supplemented with protease / phosphatase inhibitors and incubated on ice. Hs-cTnT was measured using a Cobas E 602. To analyze the fragmental ratios of serum cTnT and relative concentration of respective exosomal cTnT compared to free serum cTnT, hs-cTnT levels were also measured from the exosome-depleted serum samples and from routine phlebotomy samples as controls using the same assays.

[0209] 1.5 Immunoblotting

[0210] Exosomal lysates and matched exosome-depleted serum samples were sonicated. Proteins were denatured by heating and equal amounts were loaded onto 4-12% bis-tris gels and subsequently separated through sodium dodecyl sulfate polyacrylamide gel electrophoresis. Separated proteins were blotted onto polyvinylidene difluoride membranes and nonspecific binding sites were blocked with bovine serum albumin. Membranes were incubated with appropriate primary antibodies diluted in blocking buffer overnight. For exosomal lysates, glyceraldehyde 3-phosphate dehydrogenase was used as a loading control, whereas for exosome-depleted serum samples, transferrin was used as counterstain. After washing, membranes were incubated with species-appropriate horse radish peroxidase-conjugated secondary antibodies. Specific bands were detected by chemoluminescence. For immunoprecipitation and subsequent demonstration of cTnT from exosomes and exosome-depleted serum, pellets were lysed in a solubilization buffer containing Triton X-100 and matched exosome-depleted serum was diluted 1:1 in the same buffer for cTnT immunoprecipitation. Roche’s Ml 1-7 biotinylated anti-cTnT antibody was diluted to a final concentration of 5 pg / ml and added to the lysates and the exosome-depleted sera. Streptavidin Dynabeads were added in equal quantities to samples. The capture antibody dynabead solution was incubated overnight. Positive control was prepared using recombinant human cTnT diluted to a final concentration of 1000 pg / ml, and negative control containing vehicle only, and treated in parallel. Following incubation, captured dynabead-conjugated cTnT was separated by magnet and supernatant was carefully separated from theUniversitat Heidelberg 43 UH17314PC

[0211] dynabeads. Proteins were eluted from the beads through denaturation (for subsequent immunoblotting). Eluted denatured cTnT was loaded onto bis-tris gels as described previously.

[0212] 1.6 Roche Cobas e602 cTnT-hs

[0213] Roche’s cobas e602 high-sensitivity cTnT assay detects cTnT from serum, plasma, EDTA- or heparin-supplemented whole blood samples. Its capture antibody detects epitopes 125-131, whilst its detection antibody binds epitopes 136-147. In the reference population of 533 individuals between the ages of 20 and 71 (49.7% female), lower limit of detection was determined to be 2.85 ng / 1. 99thpercentile of cTnT concentration was found to be 14 ng / 1 overall (9 ng / 1 in females, 17 ng / 1 in males).

[0214] 1.7 Method summary

[0215] The methodology described herein allows for a time-efficient stratification of serum cardiac troponin T into exosomal and non-exosomal bound compartments, as well as quantification of total troponin T combined from both exosomal and non-exosomal compartments from a single routine blood draw, enabling the direct and reproducible detection of distinct serum cardiac troponin T signatures encompassing relative concentrations across serum compartments. In this respect, our method poses a modification of standard troponin T assays at minimal additional cost and effort to gain additional information of possible underlying myocardial pathologies associated with elevated serum cardiac troponin T levels. A potential interference of serum additives for exosome isolation and lysis was excluded in serial measurements, and longevity of exosomal isolates is warranted over a period of up to 90 days at -80°C including several freeze-thaw cycles, allowing for repeat or additional measurements as clinically indicated.

[0216] 1.8 Exosome lysis and determination of total cTn

[0217] We established a workflow for a time-effective and cost-efficient as well as highly reproducible liberation of the exosomal compartment from fresh blood samples of patients presenting to the emergency department (Chest Pain Unit) at University Hospital Heidelberg, paired with state-of-the-art quantification of exosomal troponin T and I through high-sensitive assays. Herein, lysis of the exosomal membrane can be achieved within minutes before introducing the sample to a standard troponin assay with minimal prior handling or processing required. This novel method was independently validated with standard methods for isolation of serum- or plasma-derived exosomes and liberation of exosomal molecular content.Universitat Heidelberg 44 UH17314PC

[0218] Specifically, after separation of serum or plasma from whole blood samples, 0.1% (v / v) of Triton X-100 as well as 1% (v / v) protease / phosphatase inhibitor are added to the native sample, and serum / plasma samples are exposed to ultrasonication of low-intensity for 5 cycles at 30 sec each in a rotating sonication bath, with 30 sec latency in between cycles. Hereafter, sonicated serum / plasma samples are centrifuged at 8,000 x g for 5 minutes, and supernatant was carefully separated and introduced to standard state-of-the-art troponin assays (Cobas E 411 for cTnT, Siemens ATELLICA for cTnl).

[0219] Example 2:Experiments

[0220] 2.1 Hypoxic conditioning of cardiomyoblast cell line H9c2 in vitro and subsequent EV analysis

[0221] Rat cardiomyoblast cell line H9c2 was differentiated to a cardiomyocyte-like phenotype in the presence of all-trans retinoic acid. Cells were exposed to 1.5% atmospheric 02 in a hypoxia chamber for 6 and 24 hours and control cells were incubated at normoxia. After hypoxia, cell supernatant was removed for subsequent EV isolation. Cells were washed and lysed and intracellular cTnT was demonstrated using immunoblot as described previously. EV were isolated from cell supernatants with an EV precipitation kit. After EV membrane lysis, EV-cTnT was detected using immunoprecipitation with subsequent immunoblotting as described above. For analysis of intracellular cTnT degradation, H9c2 cells were transfected with His-tagged TNNT2 plasmid and Luciferase control before differentiation. Following ATRA gavage, cells were exposed to 1.5% atmospheric 02 in a hypoxia chamber for 6 and 12 hours and control cells were incubated at normoxia. After hypoxia, cells were washed and fixed. For immunofluorescence, cell membranes were permeabilized and nonspecific binding sites were blocked with BSA. Cells were incubated with appropriate primary antibodies overnight. After washing, cells were incubated with fluorophore-conjugated secondary antibodies. Cell nuclei were counterstained with DAPI. Staining was visualized with a confocal microscope.

[0222] 2.2 Minimal invasive myocardial infarction (MiMi) mouse model

[0223] C57BL / 6 mice were used for MiMi experiments in agreement with the institutional review board for animal experiments at Regierungsprasidium Karlsruhe. Briefly, minimal-invasive needle-guided LAD occlusion or sham intervention was induced under general anesthesia as described previously (Sicklinger et al., Circ Res 2020). Four hours post intervention, mice were euthanized by cervical dislocation and a terminal blood draw was obtained for exosomeUniversitat Heidelberg 45 UH17314PC

[0224] isolation. Serum cTnT was quantified using the Cobas E 411 system, and exosomes were quantified by nanoparticle tracking analysis as described above.

[0225] 3.3 Porcine model of atrial fibrillation

[0226] To study the effects of persistent tachyarrhythmia on serum exosome release and exosomal cTnT compartmentalization in a large animal model, adult German landrace pigs were used, and all experiments were conducted after prior consent by the institutional review board for animal experiments at Regierungsprasidium Karlsruhe.

[0227] On day 0 of the experiment, blood was drawn to establish an individual baseline for each animal, and a dual pacemaker and central venous catheter were implanted as described previously (Wiedmann et al., Front Physiol 2021). Consecutively, rapid pacing was initiated to induce tachyarrhythmia, and on day 5 of persistent AF, blood was drawn for further analysis. cTnT quantification and NTA were performed as described above.

[0228] Example 3: Case studies

[0229] 3.1 Methods

[0230] EV isolation was conducted as described in Example 1.2. Adequate separation and isolation of serum EV was confirmed by detection of EV-enriched proteins CD9, annexin 5 (Anx5), TSG101 and cytosolic GAPDH by immunoblotting. EV-depleted serum served as a negative control, transferrin was used as a counterstain for EV-depleted serum samples, confirming adequate separation and appropriate purity of EV isolates by our method. Using nanoparticle tracking analysis, EV were identified and visualized based on Brownian molecular motion. Average serum EV size was found to be between 100 and 300 nm across all samples, in accordance with the typical size range of EV described in literature. To investigate longevity of EV isolates and EV-enclosed cTn under optimal storage conditions, we performed serial experiments over a period of 90 days involving several freeze-thaw cycles; herein, a significant degradation was found after 90 days at the earliest when isolates were stored at -80°C. Furthermore, to test the structural stability of EV-enclosed cTn cargo against experimentally used detergents, serum EV isolates were exposed to different soaps at concentrations and exposure conditions applied in forthcoming experiments.

[0231] 3.2 Clinical casesUniversitat Heidelberg 46 UH17314PC

[0232] Exemplary clinical case #1:

[0233] A middle-aged patient with no overt cardiovascular risk profile presents to the emergency department of a tertiary care center with unspecific symptoms not suggestive of myocardial ischemia. ECG findings are inconclusive, a stat troponin quantification from serial blood draws reveals a high-sensitive troponin T value in the observation zone with no significant kinetic indicative of myocardial infarction. Due to inconclusive results in routine tests performed in the emergency department, including a serum troponin T level of indeterminate significance, the patient is admitted with persistent symptoms. In the course of their hospitalization, resource-and cost-intense diagnostic measures, among them several imaging modalities as well as stress testing, are necessary to determine the cause of the initial symptoms and mildly elevated serum troponin T levels.

[0234] This method introduces a new diagnostic entity of serum troponins enclosed in the exosomal compartment. Isolation of exosomes from routine serum samples is achieved using differential centrifugation, density-based precipitation methods, or immunoaffinity-related methods including, but not limited to, immunoprecipitation using membrane-bound protein targets on the surface of exosomes. An exosome-containing solution is further processed to release exosome-bound troponins through mechanical dissociation including, but not limited to, sonication or structural disassembly by amphiphilic membrane intercalators, and resulting exosomal troponins can be detected and quantified by routine high-sensitive tests. Generated evidence on exosomal troponins in multiple disease contexts has concluded a specificity of serum exosomal troponin signatures to underlying cardiac pathophysiologies. Specifically, relative exosomal to free-serum troponin levels were found equivalent in free serum and exosomes of healthy controls. In the setting of myocardial necrosis in myocardial infarction, a prominent compartmental shift favoring the free-serum compartment was observed, while in acute tachyarrhythmia, a mild shift towards the free-serum compartment indicated temporary, reversible myocardial strain (Fig. 4D). These differential troponin patterns in free serum and serum-derived exosomes in the setting of myocardial ischemia detected by routine high-sensitive clinical assays were validated by compartment-specific troponin immunoprecipitation and immunoblotting (Fig. 4C), as well as in an in vitro model of cardiomyocyte hypoxia, resulting in increased exosome-bound cardiac troponin T release (Fig. 1). Thus, present evidence supports a relative exosomal troponin ratio of exosome-enclosed troponin divided by free-serum troponin quantified by high-sensitive assay to improve diagnostic specificity in the discrimination of myocardial ischemia (i.e. subclinical or clinically apparent myocardialUniversitat Heidelberg 47 UH17314PC

[0235] infarction) and myocardial strain states (arrhythmia, inflammation, volume / pressure overload), which may both incur elevated serum troponin T levels upon standard diagnostic testing.

[0236] Exemplary clinical case #2:

[0237] A 60-year-old male presents to the emergency department with an episode of palpitations and associated chest discomfort approximately six hours prior. The episode subsided spontaneously after approximately ten minutes, and he remains asymptomatic upon presentation. No prior medical history of heart disease is noted, however, a recent recording from his smart watch raises suspicion of paroxysmal atrial fibrillation. There is no ECG recording of the current symptomatic episode. Routine emergency department diagnostics reveals sinus rhythm upon presentation, and high-sensitive troponin T is mildly elevated without significant kinetic suggestive of myocardial infarction. As no emergent diagnosis can be made, the patient is discharged with the recommendation to conduct serial Holter ECG studies and urged to present again, should symptoms reoccur.

[0238] Present data obtained from the tachyarrhythmia cohort suggests that the relative exosomal troponin ratio allows not only for discrimination of myocardial pathophysiologies.

[0239] 3.3 Determining total cTn

[0240] Figure 5A illustrates a diagnostic gap in current state-of-the-art assays that may lead to unclear / inconclusive results related to hs-cTnT or hs-cTnl quantitation in routine clinical practice. As routine diagnostics include solely the free, non-exosome-bound cTnT or cTnl fraction in whole blood / serum / plasma samples, application of a readily available, rapid and low-cost methodology to access troponin T (or cTnl) enclosed within the blood exosomal compartment in circulation would result in additional information in the form of an elevated total hs-cTnT readout at minimal additional processing effort. Quantitation of total cTnT or cTnl by lysing the exosomal compartment in a sample of whole blood, serum or plasma via combined biochemical lysis and sonication, along with information on the differential compartmentalization of total cTnT or cTnl across free serum or plasma and the exosomal niche in blood preferably helps stratify patient cohorts according to underlying heart disease concomitant with cTnT (or cTnl) elevation. Herein, we postulate that free circulating cTnT or cTnl detected in routine clinical practice may derive from necrotic cardiomyocytes in the setting of overt myocardial ischemia and from exosomal decay alike. The kinetics of exosomal degradation in blood are currently unknown, which is why cTn release kinetics may not followUniversitat Heidelberg 48 UH17314PC

[0241] typical ischemic release patterns, thus accounting for often unexplained cTn ‘rise and fall’ patterns in different non-ischemic myocardial disease states. To verify this hypothesis, we first incubated exosomes with serum at 37°C to mimic the dynamics of exosomal degradation. Herein, we found a gradual increase of detected cTnT over time, pointing towards a degradation mechanism to release cTnT from a blood compartment inaccessible to standard assays, which we hypothesize to be of exosomal origin. In the next step, we treated serum from NSTEMI patients with our new methodology as specified in Fig. 5B, and quantified total cTnT compared to native serum / plasma cTnT with high-sensitive assays. Fig. 6A shows the time course of relative total cTnT / native cTnT from initial presentation to the 96 hour time mark, with a peak relative total cTnT 48 hours after initial presentation. Compared to cTnT quantitation from native serum or plasma using the same high-sensitive assay, after exosomal lysis, samples exhibited an average 19% increase in cTnT levels assumed to originate from the exosomal compartment (Fig. 6B). To rule out sonication-induced cTnT fragmentation as a confounding factor, a spike-in control of 100 pg / ml recombinant cTnT in healthy exosome-depleted plasma was introduced to the method. In the cohort of NSTEMI patient plasma, a significant increase in relative total cTnT was appreciated when compared to spike-in control, making a significant contribution of cTnT fragmentation unlikely. To validate each step of the protocol individually, the parameters of each step of cTnT liberation, including incubation time (Fig. 6C), detergent concentration (Fig. 6D), and sonication intensity (Fig. 6E), were varied to test for additional cTnT liberation potential. No incremental benefit in terms of exosomal cTnT liberation was found with the increase of each of the aforementioned experimental parameters.

[0242] The methodology described herein allows for a time- and cost-efficient liberation of blood-derived cardiac troponin T and I from the serum / plasma exosomal compartment, a biomarker pool not accessible through standard diagnostic assays. This method enables the direct quantification of a novel biomarker termed “total cardiac troponin T or I”, which comprises the summative value of free-serum or plasma cardiac troponin T / I, the current diagnostic standard for the detection of myocardial infarction or injury, combined with the exosomal fraction of cardiac troponin T or I from a single blood sample at minimal additional expense with regard to processing time and cost. Quantification of total cardiac troponin levels in serum or plasma bears the potential to increase diagnostic sensitivity and specificity in the detection of underlying myocardial pathologies commonly associated with elevated free serum or plasma troponin levels, among which are myocardial infarction, myocardial injury secondary to tachycardic arrhythmias (atrial fibrillation, AV nodal re-entry tachcardia, etc.), transientUniversitat Heidelberg 49 UH17314PC

[0243] pressure or volume overload (non-ischemic heart failure, pulmonary embolism, pulmonary hypertension), or inflammation-mediated cell membrane leakage (myocarditis, toxicity following cancer therapies). Herein, total troponin may detect a pathological increase particularly in the early stages of disease prior to an elevation of free-circulating troponin.

[0244] In summary, the data generated and presented herein perusing fresh plasma samples of patients presenting to the emergency room with suspected acute cardiovascular pathology propose a novel biomarker termed total cardiac troponin, encompassing cardiac troponins present in free serum or plasma as well as encapsulated in circulatory exosomes.

[0245] Literature

[0246] Anselmo et al. 2021, Eur Heart J, 42(28):2780-2792. doi: 10.1093 / eurheartj / ehab247 Anderson 1995, Circulation Research, vol. 76, no. 4: 681-686

[0247] Ferrieres 1998, Clinical Chemistry, 44: 487-493

[0248] Giannitsis et al. 2009, Clin Chem. 56(2) 254-261

[0249] Jaffe et al. 2012, Clin Chem 2012, 58:148-150

[0250] Lennon et al. 2022, doi : 10.1002 / ctm2.979

[0251] Masson et al. 2010, Curr Heart Fail Rep 7:15-21

[0252] Moses et al. 1999, PNAS USA 96 (6): 2645

[0253] Nolan 2002, Trends Biotechnol. 20(l):9-12

[0254] Romano & Cinti (2023), ChemRXIV, doi.org / 10.26434 / chemrxiv-2023-fhll7

[0255] Sicklinger et al. 2020, Circ Res 127(9): 1214

[0256] US 5,744,305

[0257] Wiedmann et al.2021, Front Physiol 11:629421

[0258] Wu et al. 2001, Intensive Care Med 27(6):959-61

[0259] Zara et al. 2021 doi:10.3390 / ijms22158065

[0260] Zweig 1993, Clin. Chem. 39:561-577

Claims

Universitat Heidelberg 50 UH17314PCClaims1. A method for assessing a heart disease in a subject, the method comprising(a) determining an amount of a cardiac troponin (cTn) in exosomes (exosomal cTn) in a sample of a bodily fluid of said subject; and(b) thereby assessing said heart diseasewherein assessing heart disease is differentiating between a heart disease associated with myocardial strain and a heart disease associated with myocardial ischemia, and wherein the heart disease associated with myocardial strain is atrial fibrillation, and the heart disease associated with myocardial ischemia is myocardial infarction.

2. The method of claim 1, wherein said method further comprises step (al) comparing the amount determined in step (a) to a first reference and / or calculating a score for assessing heart disease based on the amount determined in step (a).

3. The method of claim 1 or 2, wherein said sample is a blood-derived sample, preferably a serum, plasma, or blood sample.

4. The method of any one of claims 1 to 3, wherein said method further comprises step (a2) determining an amount of serum cTn in said sample and, optionally, further comprises step (a3) comparing the amount determined in step (a) to the amount determined in step (a2) and / or step (a4) comparing the amount determined in step (a2) to a second reference and / or calculating a second score for assessing heart disease based on the amount determined in step (a2).

5. The method of any one of claims 1 to 4, wherein assessing heart disease is providing data aiding in diagnosing heart disease, is excluding at least one type of heart disease, is providing information aiding a decision on further diagnostic and / or treatment steps, or is diagnosing heart disease.

6. The method of any one of claims 1 to 5, wherein assessing heart disease is assessing atrial arrhythmia and / or assessing myocardial infarction.

7. The method of any one of claims 1 to 6, wherein said subject is a mammal.Universitat Heidelberg 51 UH17314PC8. The method of any one of claims 1 to 7, wherein said cTn is cardiac troponin T (cTnT) and / or cardiac Troponin I (cTnl).

9. A computer-implemented method for assessing a heart disease in a subject, said method comprising(A) obtaining an amount of exosomal cTn in a sample of a bodily fluid of said subject; (B) comparing the amount of the exosomal cTn obtained in step (A) to a first reference and / or calculating a score for assessing heart disease based on the amount determined in step (A); and(C) assessing heart disease in said subject based on the comparison and / or the calculation made in step (B),wherein assessing heart disease is differentiating between a heart disease associated with myocardial strain and a heart disease associated with myocardial ischemia, and wherein the heart disease associated with myocardial strain is atrial fibrillation, and the heart disease associated with myocardial ischemia is myocardial infarction.

10. A database comprising stored references for amounts of exosomal cTn for assessing heart disease, tangibly embedded on a storage meanswherein assessing heart disease is differentiating between a heart disease associated with myocardial strain and a heart disease associated with myocardial ischemia, and wherein the heart disease associated with myocardial strain is atrial fibrillation, and the heart disease associated with myocardial ischemia is myocardial infarction.

11. A system comprising an evaluation device with a data processor, the evaluation device comprising instructions for providing an assessment of a heart disease based on an amount of exosomal cTn obtained by the evaluation devicewherein assessing heart disease is differentiating between a heart disease associated with myocardial strain and a heart disease associated with myocardial ischemia, and wherein the heart disease associated with myocardial strain is atrial fibrillation, and the heart disease associated with myocardial ischemia is myocardial infarction.

12. The system of claim 11, wherein said comparison and / or said calculation is performed according to the method according to any one of claims 1 to 8.Universitat Heidelberg 52 UH17314PC13. The system of claim 11 or 12, further comprising, operatively connected to the data processor, an analytic device configured for determining said exosomal cTn in said sample.

14. A kit for assessing heart disease in a subject comprising a detection agent for determining an amount of a cTn and an agent liberating cTn from exosomes wherein assessing heart disease is differentiating between a heart disease associated with myocardial strain and a heart disease associated with myocardial ischemia, and wherein the heart disease associated with myocardial strain is atrial fibrillation, and the heart disease associated with myocardial ischemia is myocardial infarction.

15. A method for determining an amount of a total cTn in a sample of a subject, the method comprising(i) contacting said sample with a chemical means and / or a physical means for lysing exosomes,(ii) determining an amount of a cTn in the sample obtained in step (i), and, thereby (iii) determining the amount of a total cTn in said sample.

16. The method of claim 15, wherein step (i) comprises contacting said sample with a chemical means and a physical means for lysing exosomes.

17. The method of claim 15 or 16, wherein said chemical means is a detergent, preferably a Triton, more preferably Triton-XIOO.

18. The method of any one of claims 15 to 17, wherein said physical means is ultrasonication, preferably low-intensity ultrasonication.

19. A method for assessing a heart disease in a subject, the method comprising the steps of the method for determining an amount of a total cTn in a sample of a subject of any one of claims 15 to 18, and thereby assessing said heart disease.